documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item c cybersecurity item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines including biologic therapies vaccines animal health products companys operations principally managed product basis include two operating segments pharmaceutical animal health reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers farmers pet owners june merck completed spinoff spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales total company sales including sales companys top pharmaceutical products well sales animal health products follows millions total sales pharmaceutical keytruda gardasilgardasil januviajanumet proquadmmr iivarivax bridion lagevrio alliance revenue lynparza alliance revenue lenvima rotateq vaxneuvance animal health livestock companion animal revenues alliance revenue represents mercks share profits product sales net cost sales commercialization costs revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities well revenue thirdparty manufacturing arrangements table contents pharmaceutical pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders human health vaccine products consist preventive pediatric adolescent adult vaccines certain products within companys franchises follows oncology keytruda antipd programmed death receptor therapy approved monotherapy treatment certain patients cervical cancer classical hodgkin lymphoma cutaneous squamous cell carcinoma esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr solid tumors including msihdmmr colorectal cancer endometrial carcinoma nonsmallcell lung cancer nsclc primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh solid tumors urothelial cancer including nonmuscle invasive bladder cancer keytruda also approved monotherapy adjuvant treatment certain patients melanoma certain patients renal cell carcinoma rcc postsurgery keytruda approved adjuvant treatment following resection platinumbased chemotherapy certain patients nsclc additionally keytruda approved patients certain types resectable nsclc combination chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery keytruda also approved patients highrisk early stage triplenegative breast cancer tnbc combination chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery addition keytruda approved combination chemotherapy treatment certain patients advanced nsclc combination chemotherapy certain types advanced biliary tract cancer combination chemotherapy without bevacizumab advanced cervical cancer combination chemotherapy advanced esophageal cancer combination trastuzumab chemotherapy certain patients advanced human epidermal growth factor receptor herpositive gastric gej adenocarcinoma pdl cps combination chemotherapy advanced hernegative gastric gej adenocarcinoma combination chemotherapy hnscc combination chemotherapy advanced tnbc combination axitinib advanced rcc combination lenvima lenvatinib patients advanced rcc certain types advanced endometrial carcinoma combination enfortumab vedotin adult patients locally advanced metastatic urothelial cancer welireg belzutifan medication treatment adult patients certain von hippellindau diseaseassociated tumors treatment adult patients advanced rcc following pd programmed deathligand pdl inhibitor vascular endothelial growth factor tyrosine kinase inhibitor addition company recognizes alliance revenue related sales lynparza olaparib oral poly adpribose polymerase parp inhibitor certain types advanced recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancers alliance revenue related sales lenvima oral receptor tyrosine kinase inhibitor certain types thyroid cancer rcc hcc combination everolimus certain patients advanced rcc combination keytruda certain patients advanced endometrial carcinoma advanced rcc alliance revenue related reblozyl luspatercept aamt treatment certain types anemia vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain cancers diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children vaxneuvance pneumococcal valent conjugate vaccine vaccine help prevent invasive pneumococcal disease individuals weeks age older pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease vaqta hepatitis vaccine inactivated indicated prevention disease caused hepatitis virus persons months age older hospital acute care bridion sugammadex medication reversal two types neuromuscular blocking agents used surgery prevymis letermovir prophylaxis cytomegalovirus cmv infection disease cmv disease certain high risk adult recipients allogeneic hematopoietic stem cell transplant kidney transplant respectively dificid fidaxomicin treatment c difficileassociated diarrhea zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain table contents bacterial infections noxafil posaconazole antifungal agent prevention certain invasive fungal infections primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infections cardiovascular adempas riociguat cardiovascular drug treatment chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension certain patients verquvo vericiguat medicine reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics certain adults symptomatic chronic heart failure reduced ejection fraction virology lagevrio investigational oral antiviral covid medicine available us emergency use authorization eua isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection neuroscience belsomra suvorexant orexin receptor antagonist indicated treatment insomnia characterized difficulties sleep onset andor sleep maintenance immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases remicade infliximab treatment inflammatory diseases company markets europe russia trkiye diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes animal health animal health segment discovers develops manufactures markets wide range veterinary pharmaceuticals vaccines health management solutions services well extensive suite digitally connected identification traceability monitoring products principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish aquaflor florfenicol antibiotic farmraised fish flexolt fluralaner lice sheep allflex livestock intelligence solutions animal identification monitoring traceability companion animal products bravecto line oral topical parasitic control products including original bravecto fluralaner products dogs cats last weeks bravecto fluralaner onemonth monthly product dogs bravecto plus fluralanermoxidectin twomonth product cats sentinel line oral parasitic products dogs including sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tabs milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine lines flexible dog cat vaccination gilvetmab immune checkpoint inhibitor monoclonal antibody conditionally licensed melanoma mastocytoma tumors otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionmometamax ultra gentamicin sulfate mometasone furoate monohydrate posaconazole suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line table contents horses scalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies sure petcare products companion animal identification wellbeing including microchip pet recovery system home discussion sales companys products see item managements discussion analysis financial condition results operations product approvals set forth summary significant product approvals received company date product date approval us food drug administration fda approval single agent adjuvant treatment following surgical resection platinumbased chemotherapy adult patients stage ib ta cm ii january iiia nsclc based keynote trial fda full approval treatment adult pediatric patients unresectable metastatic msi h dmmr solid tumors progressed following prior treatment satisfactory alternative treatment options conversion accelerated full regular approval based march keynote keynote keynote trials fda accelerated approval combination padcev enfortumab vedotinejfv treatment adult patients locally advanced metastatic urothelial carcinoma eligible cisplatincontaining chemotherapy based keynote trial dose escalation cohort cohort april cohort k conducted collaboration seagen pfizer inc pfizer astellas japans ministry health labor welfare mhlw approval treatment patients june relapsed refractory pmbcl based keynote keynotea trials european commission ec approval combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy firstline treatment locally advanced unresectable august metastatic herpositive gastric gej adenocarcinoma adults whose tumors express pdl based keynote trial keytruda chinas national medical products administration nmpa approval monotherapy treatment adult patients advanced unresectable metastatic msih dmmr solid tumors including patients colorectal cancer progressed following treatment fluoropyrimidine oxaliplatin irinotecan solid tumors progressed following prior therapy september satisfactory alternative treatment options based keynote keynote trials october ec approval monotherapy adjuvant treatment adults nsclc high risk recurrence following complete resection platinumbased chemotherapy based keynote trial fda approval treatment patients resectable tumors cm node positive nsclc october combination platinumcontaining chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery based keynote trial fda full approval treatment adult pediatric patients recurrent locally advanced metastatic merkel cell carcinoma conversion accelerated full regular approval october based keynote keynote trials october fda approval combination gemcitabine cisplatin treatment patients locally advanced unresectable metastatic biliary tract cancer based keynote trial table contents fda approval combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment adults locally advanced unresectable metastatic hernegative gastric november gej adenocarcinoma based keynote trial fda full approval combination padcev enfortumab vedotinejfv antibodydrug conjugate treatment adult patients locally advanced metastatic urothelial cancer conversion december accelerated full regular approval based keynotea trial conducted collaboration seagen pfizer astellas ec approval combination fluoropyrimidine platinumcontaining chemotherapy first line treatment locally advanced unresectable metastatic hernegative gastric gej december adenocarcinoma adults whose tumors express pdl based keynote trial ec approval combination gemcitabine cisplatin firstline treatment locally december advanced unresectable metastatic biliary tract carcinoma adults based keynote keytruda trial chinas nmpa approval combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment patients locally advanced unresectable metastatic hernegative december gastric gej adenocarcinoma based keynote trial fda approval combination chemoradiotherapy treatment patients figo january international federation gynecology obstetrics stage iiiiva cervical cancer based keynotea trial fda full approval treatment patients hcc secondary hepatitis b received january prior systemic therapy pdpdl containing regimen conversion accelerated full regular approval based keynote trial chinas nmpa approval combination gemcitabine cisplatin firstline treatment february patients locally advanced metastatic biliary tract carcinoma based keynote trial fda approval combination abiraterone prednisone prednisolone treatment adult patients deleterious suspected deleterious brcamutated brcam metastatic may castrationresistant prostate cancer mcrpc based propel trial lynparza japans mhlw approval combination abiraterone prednisolone treatment adult august patients brcam mcrpc distant metastasis based propel trial fda approval cmv prophylaxis donor cmvseropositiverecipient cmvseronegative adult kidney june transplant recipients based p trial prevymis ec approval cmv prophylaxis donor cmvseropositiverecipient cmvseronegative adult kidney november transplant recipients based p trial fda approval expanded indication prevention disease caused zaire ebolavirus individuals months age older vaccine previously approved use individuals august years age older ervebo ec approval expanded indication active immunization individuals one year age older protect ebola virus disease caused zaire ebolavirus vaccine previously approved september use eu individuals years age older fda approval treatment adult patients advanced rcc following pd pdl welireg december inhibitor vascular endothelial growth factor tyrosine kinase inhibitor based litespark trial ec approval injectable formulation dogs persistent killing fleas ticks months bravecto january treatment jointly developed commercialized worldwide collaboration astrazeneca table contents competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company wellpositioned compete search technological innovations company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products well competitors products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access changes us health care system part health care reform enacted prior years well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys sales performance negatively affected costreduction measures taken governments third parties lower health care costs us biden administration congress continue discuss legislation designed control health care costs including cost drugs company anticipates actions additional actions future continue negatively affect sales profits united states company faces increasing pricing pressure managed care organizations government agencies programs could negatively affect companys sales profit margins including practices managed care organizations federal state exchanges institutional governmental purchasers ii federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act aca american rescue plan act american rescue plan act inflation reduction act ira us federal state governments many years pursued methods reduce cost drugs vaccines pay example federal state laws require company pay specified rebates medicines reimbursed medicaid provide discounts medicines purchased certain state federal entities department defense veterans affairs public health service entities hospitals serving disproportionate share low income uninsured patients additionally us consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers pbms consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining placement unfavorable pricing could adversely affect revenue addition formulary table contents tier copay differentials private health insurance companies selfinsured employers increasing costsharing required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product requiring patient first fail one generic products permitting access branded medicine management tools also used treatment areas payor taken position multiple branded products therapeutically comparable us payor market concentrates company may face greater pricing pressure private thirdparty payors order provide information companys pricing practices company annually posts website pricing transparency report us report provides companys average annual list price net price increases average discounts across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns legislative changes congress passed ira makes significant changes drugs covered paid medicare program including creation financial penalties drugs whose prices rise faster rate inflation redesign medicare part program require manufacturers bear liability certain drug benefits government pricesetting certain medicare part drugs starting medicare part b drugs starting august us department health human services hhs centers medicare medicaid services cms announced januvia included first year iras drug price negotiation program program pursuant iras program discussions government occurred continue government price setting becoming effective january company sued us government regarding iras program see item financial statements supplementary data note contingencies environmental liabilities furthermore biden administration congress continue discuss legislation designed control health care costs including cost drugs longterm implications ira remain uncertain subject various factors including manner us department health human services decides implement statute many experts analysts within industry outside predicted law harm innovation pharmaceutical industry result fewer new treatments developed approved time merck working mitigate potentially harmful effects law could could include detrimental impact innovation addition congress passed american rescue plan act included provision eliminates statutory cap rebates drug manufacturers pay medicaid beginning january rebates act discount list price eliminating cap means manufacturer discounts paid medicaid increase prior change manufacturers required pay average manufacturer price amp rebates state medicaid programs medicaidcovered drugs result provision beginning manufacturers may pay state medicaid programs rebates received sales particular products change presents risk merck drugs high medicaid utilization rebate exposure amp company also faces increasing pricing pressure states looking exert greater influence price prescription drugs number states passed pharmaceutical price cost transparency laws laws typically require manufacturers report certain product price information financial data state laws also require manufacturers provide advance notification price increases company expects states continue focus pharmaceutical pricing increasingly shift aggressive price control tools prescription drug affordability boards authority conduct affordability reviews establish upper payment limits addition recently fda authorized two year period floridas application import prescription drugs canada table contents regulatory changes pharmaceutical industry also could considered potential source savings via legislative administrative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls european union efforts toward health care cost containment remain intense european union eu company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries eu attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs reference pricing may either compare products prices markets external reference pricing compare products price products national class internal reference pricing authorities use price data set new local prices brandname drugs including companys drugs guidelines examining reference pricing usually set local markets changed pursuant local regulations eu member states established freepricing systems regulate pricing drugs profit control plans others seek negotiate set prices based costeffectiveness product assessment whether offers therapeutic benefit products relevant class downward pressure health care costs general particularly prescription drugs become intense result increasingly high barriers erected entry new products eu member states crossborder imports lowpriced markets also exert competitive pressure may reduce pricing within eu member state additionally eu member states power restrict range pharmaceutical products national health insurance systems provide reimbursement eu pricing reimbursement plans vary widely member state member state eu member states provide drug products may marketed reimbursement price agreed eu member states may require completion additional studies compare costeffectiveness particular product candidate already available therapies socalled health technology assessment hta order obtain reimbursement pricing approval hta pharmaceutical products becoming increasingly common part pricing reimbursement procedures eu member states hta process governed national laws countries involves assessment cost effectiveness public health impact therapeutic impact andor economic social impact use given pharmaceutical product national health care system individual country conducted ultimately hta measures added value new health technology compared existing ones outcome htas regarding specific pharmaceutical products often influence pricing reimbursement status granted pharmaceutical products regulatory authorities individual eu member states negative hta one companys products may mean product reimbursable may force company reduce reimbursement price offer discounts rebates negative hta leading recognized hta body could also undermine companys ability obtain reimbursement relevant product outside jurisdiction example eu member states yet developed hta mechanisms may rely extent hta performed countries developed hta framework inform pricing reimbursement decisions hta procedures require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement obtain reimbursement pricing approval eu member states company may required conduct studies compare cost effectiveness companys product candidates therapies considered local standard care assurance eu member state allow favorable pricing reimbursement market access conditions companys products feasible conduct additional costeffectiveness studies required japan japan pharmaceutical industry subject governmentmandated annual price reductions pharmaceutical products certain vaccines furthermore government order repricings specific products determines use product exceed certain thresholds defined applicable repricing rules addition merck product medical action composition another product subject market expansion pricing merck product could also subject repricing unless meets exception criteria next governmentmandated price reduction occur april table contents china companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls recent years chinese government introduced implemented number structural reforms accelerate shift innovative products reduce costs since multiple new policies introduced government improve access new innovation reduce complexity regulatory filings accelerate review approval process led significant increase number new products approved year mechanism drugs added governments national reimbursement drug list nrdl evolves inclusion may require price negotiation could impact outlook market selected brands new nrdl recently completed new entries averaged price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution volume based procurement vbp government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered last five rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward emerging markets companys focus emerging markets addition china continued governments many emerging markets also focused constraining health care costs enacted price controls measures impacting intellectual property including exceptional cases threats compulsory licenses aim put pressure price innovative pharmaceuticals result constrained market access innovative medicine company anticipates pricing pressures market access challenges continue future varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability changes trade sanctions embargoes significant currency fluctuation controls financial crises limited changing availability funding health care credit worthiness health care partners hospitals developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing global cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes wellpositioned respond evolving health care environment market forces regulation pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda us administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market us time fda committed expediting development review products bearing breakthrough therapy designation accelerated table contents regulatory review process medicines designation fda also undertaken efforts bring generic competition market efficiently timely manner eu adopted directives legislation concerning classification approval marketing labeling advertising manufacturing wholesale distribution integrity supply chain pharmacovigilance safety monitoring medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states particular eu regulators may approve products subject number postauthorization conditions examples typical postauthorization commitments include additional pharmacovigilance conduct clinical trials establishment patient registries physician patient education controlled distribution prescribing arrangements noncompliance postauthorization conditions pharmacovigilance obligations lead regulatory action including variation suspension withdrawal marketing authorizations enforcement regulatory actions including imposition financial penalties companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes collaboration key stakeholders role play helping ensure science advances health care products accessible affordable company committed ensuring reliable safe global supply quality medicines vaccines developing testing implementing innovative solutions address barriers access affordability medicines vaccines companys approach designed enable serve greatest number patients today meeting needs patients future company 's wideranging efforts expand access health encompass set principles embedded business strategies operations principles guide company 's global approach addressing significant public health burdens unmet medical needs company systematically evaluates pipeline candidates assess potential lowresource settings throughout life cycle products company seeks continually evaluate potential adapt changes external environment collaborating various stakeholders including private governmental multilateral nonprofit organizations company seeks design deliver sustainable solutions address access challenges payer provider patient levels furthermore company incorporates access health metrics scorecard making component calculating annual incentive pay majority global employees addition social investments including philanthropic programs impact investing merck helping strengthen health systems build capacity particularly underresourced communities merck patient assistance program provides certain medicines adult vaccines free people us prescription drug health insurance coverage without companys assistance afford merck medicines vaccines globally merck made substantial contributions access health key initiatives including product donations humanitarian assistance lowincome countries medical outreach program mectizan donation program longest running diseasespecific drug donation program kind supports elimination two neglected tropical diseases onchocerciasis lymphatic filariasis additionally merck mothers company provides funding scientific business acumen help global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent grantmaking organization supports variety organizations dedicated addressing systemic barriers health equity privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including eu general data protection regulation gdpr imposes penalties global revenue gdpr related implementing laws individual eu member states govern collection use personal health data personal data eu gdpr increased responsibility liability relation personal data company processes also imposes number strict obligations restrictions table contents ability process includes collection analysis transfer personal data including health data clinical trials adverse event reporting gdpr also includes requirements relating consent individuals personal data relates information provided individuals prior processing personal data personal health data notification data processing obligations national data protection authorities security confidentiality personal data gdpr prohibits transfer personal data countries outside eu considered ec provide adequate level data protection including us except data controller meets specific requirements following schrems ii decision court justice eu considerable uncertainty permissibility international data transfers gdpr light implications decision company may face difficulties regarding transfer personal data eu third countries since company entered euapproved standard contractual clauses vendors suppliers collaboration partners clinical trial sites order facilitate lawful transfer personal data eu us addition president biden issued executive order october address data privacy concerns raised schrems ii decision introducing among measures safeguards oversight personal data collection us signals intelligence activities providing individuals redress mechanism us data protection concerns certainty international transfer personal data eu via euus data privacy framework successor invalidated euus privacy shield came way new eu adequacy decision issued ec july however new adequacy decision already contested privacy advocates subject legal review failure comply requirements gdpr related national data protection laws eu member states may result significant monetary fines administrative penalties well civil liability claims individuals whose personal data processed data protection authorities different eu member states may still implement certain variations enforce gdpr national data protection laws differently introduce additional national regulations guidelines adds complexity processing personal data eu guidance developed eu level national level individual eu member states concerning implementation compliance practices often updated otherwise revised moreover growing trend towards required public disclosure clinical trial data eu adds complexity obligations relating processing health data clinical trials failing comply obligations could lead government enforcement actions significant penalties company harm reputation adversely impact business operating results uncertainty regarding interplay different regulatory frameworks adds complexity company faces regard data protection regulation august china passed personal information protection law pipl aims standardize handling personal information china became effective november pipl currently applies processing personal information natural persons china processing personal information outside china purpose provide products services china analyze activities individuals china similar gdpr pipl contains unique requirements found gdpr company developed implemented comprehensive plans ensure compliance pipl plans relating data localization crossborder transfers pending forthcoming guidance cyberspace administration china additional laws regulations enacted certain states us canada europe asia latin america increased enforcement litigation activity us developed markets well increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving requirements risks facilitate transfer personal information across international borders distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pbms institutions human health vaccines sold primarily physicians wholesalers distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers farmers pet owners table contents raw materials company obtains raw materials essential business numerous suppliers worldwide principal materials company uses manufacturing operations available one source however company obtains certain raw intermediate materials primarily one source company attempts possible mitigate potential risk associated raw materials components supplies inventory appropriate supplier management patents trademarks licenses patent protection considered aggregate material importance companys marketing products us major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products patent protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity key patents may subject patent term restoration also known patent term extension pte five years us japan certain jurisdictions europe five years extended term may available form supplementary protection certificate spc ptes spcs awarded offset portion patent term lost clinical testing regulatory review process product prior approval food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity added patent term orange booklisted patents regulatory data exclusivity term small molecule biologic products us indications new currently marketed drugs certain agreed upon pediatric studies completed applicant eu also provides additional six months pediatric market exclusivity attached products spc term japan attaches additional term pediatric studies market exclusivity extension unrelated patent term regulatory data exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity products patent portfolio us regulatory data protection term generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication twelve years first marketing approval biological product table contents table provides list expiration dates include pending pte spc periods indicated key patent protection us eu japan china following marketed products product year expiration us year expiration eu year expiration japan year expiration china januvia expired expired janumet expired na expired janumet xr na na expired isentress expired expired simponi na na na lenvima expired bridion expired expired expired bravecto pending pte gardasil expired expired expired gardasil keytruda lynparza pending pte zerbaxa na adempas na expired belsomra na na prevymis pending pte vaxneuvance patent patent na delstrigo pending pte na pifeltro pending pte welireg pending pte na na na note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities na currently marketing approval eu date represents expiration date following four countries france germany italy spain major eu markets spc applications filed granted major eu markets patent expiry date spc expiry date listed pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date result settlement agreements related patent directed specific sitagliptin salt form products exclusivity extend may januvia janumet july janumet xr generic entry anticipated expiry date reflects granted pte mg tablet japan company marketing rights us japan china distribution agreement johnson johnson innovative medicine expires october part global strategic oncology collaboration eisai co ltd eligible six months pediatric market exclusivity part global strategic oncology collaboration astrazeneca commercialized worldwide collaboration bayer ag company marketing rights us pte pending included listed patent expiry date data exclusivity granted us expires july data exclusivity granted eu japan expires december september respectively table contents company following key us patent protection drug candidates review us fda currently anticipated review us year expiration us mk gefapixant mk sotatercept mk patritumab deruxtecan v pneumococcal vaccine received complete response letter fda december biologic product mk sotatercept eligible years data exclusivity upon approval us granted patents covering methods treating pulmonary arterial hypertension mk sotatercept expire absent pte may also provide additional exclusivity company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us mka doravirine islatravir pending pte doravirine patent mka quavonlimab pembrolizumab mk nemtabrutinib mka vibostolimab pembrolizumab mka favezelimab pembrolizumab v mk clesrovimab mk bomedemstat mk mk lagevrio mk mka pembrolizumab hyaluronidase subcutaneous mk mk tulisokibart developed collaboration received emergency use authorization fda treatment highrisk adults mild moderate covid unless otherwise noted patents tables compound patents drug candidates review development key us patents may subject future pte five years andor six month pediatric market exclusivity addition depending circumstances surrounding final regulatory approval product may granted patents pending patent applications could relevance product finally approved expiration compound patent generally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived laterexpiring patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv us certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical product sales may also depend upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought us countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought us countries reform patent relevant laws implementation international treaties table contents information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities company prioritizes research development efforts focuses candidates believes represent breakthrough science unmet medical needs make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research acquisitions well licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases metabolic diseases infectious diseases neurosciences immunology respiratory diseases vaccines development human health products industry practice government regulations us foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed us recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate table contents safety tolerability immunogenicity vaccine candidate phase studies doseranging studies provide additional data safety immunogenicity andor effectiveness finally phase trials conducted intended population licensure provide data immunogenicity andor effectiveness well safety support applications regulatory approvals successful company submits regulatory filings appropriate regulatory agencies united states us fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act vii pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete original efficacy supplements nda bla fda review period target six months priority review ten months standard review time supplemental application received review timelines determined fda generally act upon application within timeline goals unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review one special designations granted given application ie product designated breakthrough therapy may also eligible priority review due covid public health crisis us secretary health human services secretary exercised statutory authority determine public health emergency existed declared circumstances justified emergency use drugs biological products authorized fda secretary issued amended determination public health emergency significant potential public health emergency existed declared circumstances continued justify authorization emergency use products effect declaration amended enables fda issue emergency use authorizations euas permitting distribution use specific medical products absent ndabla submission approval including products treat prevent diseases conditions caused sarscov virus subject terms euas fda must make certain findings grant eua including reasonable believe based totality evidence drug biologic may effective known potential benefits used terms eua outweigh known potential risks additionally fda must find adequate approved available alternative emergency use authorized drug biologic fda may revise revoke eua circumstances justifying issuance longer exist criteria issuance longer met circumstances make revision revocation appropriate protect public health safety european union primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds table contents products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure eu member states markets outside us eu company submits marketing applications national regulatory authorities examples ministry health labour welfare japan national medical products administration china health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market us eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review us internationally latestage clinical development mk patritumab deruxtecan potential firstinclass directed dxd antibody drug conjugate adc priority review fda treatment adult patients locally advanced metastatic egfrmutated nsclc previously treated two systemic therapies bla based primary results herthenalung pivotal phase trial data results presented iaslc world conference lung cancer simultaneously published journal clinical oncology fda set pdufa date june bla priority review follows receipt breakthrough therapy designation granted fda december bla reviewed realtime oncology review program patritumab deruxtecan herdxd discovered daiichi sankyo jointly developed daiichi sankyo merck mk sotatercept mercks novel investigational activin signaling inhibitor priority review fda treatment adult patients pulmonary arterial hypertension world health organization group application based results phase stellar trial fda set pdufa date march sotatercept also review ema sotatercept granted breakthrough therapy designation orphan drug designation fda well priority medicines prime scheme orphan drug designation ema treatment pulmonary arterial hypertension sotatercept subject licensing agreement bristolmyers squibb company bms v companys investigational valent pneumococcal conjugate vaccine specifically designed help prevent invasive pneumococcal disease pneumococcal pneumonia adults priority review fda bla v supported results multiple phase clinical studies evaluating v vaccinenave vaccineexperienced adult patient populations including stride stride stride stride fda set pdufa date june v granted breakthrough therapy designation fda prevention invasive pneumococcal disease pneumococcal pneumonia caused streptococcus pneumoniae serotypes ac f n f bc f f f b f f b adults years age older mk gefapixant nonnarcotic oral selective px receptor antagonist treatment refractory unexplained chronic cough adults december fda issued second crl regarding resubmission mercks nda gefapixant crl fda concluded mercks application meet substantial evidence effectiveness treating refractory chronic cough unexplained chronic cough crl related safety gefapixant merck reviewing fdas feedback determine next steps mk keytruda antipd therapy approved treatment many cancers clinical development expanded indications studies encompass cancer types including biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial many currently phase clinical development trials planned cancers keytruda priority review fda combination standard care chemotherapy carboplatin paclitaxel followed keytruda single agent treatment patients primary table contents advanced recurrent endometrial carcinoma based keynote trial fda set pdufa date june supplemental bla keytruda review eu japan perioperative treatment regimen patients resectable stage ii iiia iiib nsclc based keynote study perioperative treatment regimen includes treatment surgery neoadjuvant continued surgery adjuvant february emas committee medicinal products human use chmp adopted positive opinion recommending approval keytruda combination platinumcontaining chemotherapy neoadjuvant treatment continued monotherapy adjuvant treatment treatment resectable nsclc high risk recurrence adults based keynote trial chmps recommendation reviewed ec marketing authorization eu final decision expected first half addition keytruda review eu japan combination padcev enfortumab vedotinejfv adc treatment adult patients locally advanced metastatic urothelial carcinoma based keynotea trial conducted collaboration seagen pfizer astellas keytruda also review eu combination chemoradiotherapy treatment patients highrisk locally advanced cervical cancer based keynotea trial additionally keytruda review japan combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment patients locally advanced unresectable metastatic gastric gej adenocarcinoma based keynote trial keytruda also review japan combination standard care chemotherapy gemcitabine cisplatin treatment patients locally advanced unresectable metastatic biliary tract cancer based keynote trial welireg review eu treatment previously treated advanced renal cell carcinoma based lightspark clinical trial treatment von hippellindau disease based lightspark clinical trial company diversifying oncology portfolio executing strategy broadly based three strategic pillars immunooncology precision molecular targeting tissue targeting merck numerous phase oncology programs within pillars immunooncology keytruda therapeutic areas cutaneous squamous cell hepatocellular mesothelioma ovarian smallcell lung cancers mka coformulation quavonlimab mercks novel investigational antictla antibody pembrolizumab evaluated treatment rcc subcutaneous mka coformulation pembrolizumab hyaluronidase evaluated comparability intravenous formulation pembrolizumab certain types nsclc mka coformulation favezelimab mercks novel investigational antilag therapy pembrolizumab evaluated treatment colorectal cancer hematological malignancies mka coformulation vibostolimab antitigit therapy pembrolizumab evaluated treatment certain types melanoma nsclc sclc v mrna investigational individualized neoantigen therapy evaluated combination keytruda adjuvant treatment patients certain types melanoma interpath clinical trial fda ema granted breakthrough therapy designation prime scheme respectively v mrna combination keytruda adjuvant treatment patients certain stages highrisk melanoma following complete resection v mrna also evaluated phase interpath clinical trial adjuvant treatment certain patients nsclc v developed part collaboration moderna precision molecular targeting mk lynparza oral parp inhibitor developed part collaboration astrazeneca plc company currently evaluating lynparza combination pembrolizumab expanded indications therapeutic areas nsclc sclc mk lenvima oral receptor tyrosine kinase inhibitor evaluated combination keytruda expanded indications therapeutic areas esophageal gastric cancers lenvima developed part collaboration eisai co ltd table contents mk nemtabrutinib oral reversible noncovalent brutons tyrosine kinase btk inhibitor evaluated treatment hematological malignancies including chronic lymphocytic leukemia small lymphocytic lymphoma mk bomedemstat investigational orally available lysinespecific demethylase inhibitor evaluated treatment certain patients essential thrombocythemia bomedemstat fda orphan drug fast track designation treatment essential thrombocythemia myelofibrosis orphan drug designation treatment acute myeloid leukemia priority medicines prime scheme designation ema treatment myelofibrosis mk investigational cytochrome p cypa inhibitor evaluated treatment certain patients metastatic castration resistant prostate cancer mk developed part collaboration orion corporation tissue targeting mk investigational trophoblast cellsurface antigen tropdirected adc evaluated certain patients nsclc certain patients previously treated endometrial carcinoma mk developed part collaboration kelunbiotech company also terminated certain phase oncology development programs company discontinued development ladiratuzumab vedotin adc targeting liv developed collaboration seagen inc pfizer additionally december company pfizer terminated license codevelopment agreement tukysa tucatinib december merck announced stopping phase keylynk trial evaluating keytruda combination maintenance lynparza treatment patients metastatic squamous nsclc merck discontinued study based recommendation independent data monitoring committee reviewed data planned interim analysis interim analysis keytruda combination chemotherapy followed keytruda plus lynparza demonstrate improvement overall survival one studys dual primary endpoints compared keytruda combination chemotherapy followed keytruda plus placebo also december merck eisai announced phase leap trial evaluating keytruda plus lenvima meet dual primary endpoints overall survival progressionfree survival firstline treatment patients advanced recurrent endometrial carcinoma whose disease mismatch repair proficient pmmrnot microsatellite instabilityhigh msih mismatch repair deficient dmmrmsih final analysis keytruda plus lenvima improve overall survival progressionfree survival sufficiently meet studys prespecified statistical criteria versus standard care platinumbased chemotherapy doublet carboplatin plus paclitaxel companies work investigators share results scientific community additionally company currently candidates phase clinical development several therapeutic areas mk investigational oral proprotein convertase subtilisinkexin type pcsk inhibitor evaluated hypercholesterolemia first participants enrolled two registrational phase studies evaluating lowdensity lipoprotein ldl cholesterol reduction phase cardiovascular outcomes study mk clesrovimab respiratory syncytial virus rsv monoclonal antibody evaluated prevention rsv medically attended lower respiratory tract infection infants certain children one year age mk tulisokibart humanized monoclonal antibody directed tumor necrosis factorlike ligand target associated intestinal inflammation fibrosis evaluated treatment ulcerative colitis mka new doravirineislatravir oncedaily oral combination doravirine mg lower dose islatravir evaluated beginning phase program previously untreated adults switch antiretroviral therapy virologically suppressed adults mk islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti evaluated treatment hiv infection december fda placed clinical holds islatravir investigational new drug applications based observations decreases total lymphocyte cd tcell counts participants receiving islatravir clinical studies phase clinical trial evaluating oral onceweekly combination lower dose islatravir gilead sciences lenacapavir virologically suppressed adults completed enrollment investigational ndas doravirineislatravir islatravir table contents lenacapavir onceweekly treatment regimens remain partial clinical hold studies would use islatravir doses higher doses considered revised clinical programs mk lagevrio investigational oral antiviral medicine treatment mild moderate covid adults risk progressing severe disease merck developing lagevrio collaboration ridgeback biotherapeutics lp ridgeback fda granted emergency use authorization lagevrio december last reissued october lagevrio authorized treatment adults current diagnosis mild moderate covid high risk progression severe covid including hospitalization death alternative covid treatment options approved authorized fda accessible clinically appropriate authorization based phase moveout trial lagevrio approved use us authorized duration declaration circumstances exist justifying authorization emergency use food drug cosmetic act unless authorization terminated revoked sooner november ema issued positive scientific opinion lagevrio intended support national decisionmaking possible use lagevrio prior marketing authorization october ema initiated rolling review lagevrio treatment covid adults february merck ridgeback announced committee medicinal products human use chmp ema recommended refusal marketing authorization application maa lagevrio merck ridgeback appealed decision requested reexamination maa june merck ridgeback announced withdrawn eu application marketing authorization lagevrio based chmps view data submitted sufficient satisfy eu regulatory requirements marketing authorization lagevrio applications regulatory bodies review chart reflects companys research pipeline february candidates shown phase include date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect cancer additional claims line extensions formulations inline products shown phase cancer cancer cancer mk quavonlimab mk boserolimab mk lenvima nonsmallcell lung neoplasm malignant head neck mka quavonlimabpembrolizumab mk welireg dengue fever virus vaccine colorectal endometrial v mk zilovertamab vedotin esophageal hiv infection hematological malignancies hepatocellular mkb islatravirmk mk ifinatamab deruxtecan prostate mkd islatravirlenacapavir smallcell lung rare cancers hiv prevention mk mk lynparza mk neoplasm malignant advanced solid tumors nonalcoholic steatohepatitis nash mk keytruda mka vibostolimabpembrolizumab mk efinopegdutide advanced solid tumors biliary pulmonary arterial hypertension prostate bladder mk mka pembrolizumabhyaluronidase subcutaneous breast pulmonary hypertension due left heart disease cutaneous squamous cell cervical mk sotatercept mk favezelimab colorectal schizophrenia nonsmallcell lung endometrial mk mka favezelimabpembrolizumab esophageal systemic lupus erythematosus bladder gastric mk cutaneous squamous cell head neck thrombosis endometrial hepatocellular mk esophageal ovarian melanoma prostate renal cell table contents phase phase entry date review antiviral covid new molecular entities certain supplemental filings mk lagevrio us may cancer cancer cancer mk patritumab deruxtecan mk keytruda mk patritumab deruxtecan nonsmallcell lung us primary advanced recurrent endometrial carcinoma nonsmallcell lung may eu mk welireg keynote us mk nemtabrutinib von hippellindau vhl disease eu resectable stage ii iiia iiib nsclc hematological malignancies march cough keynote eu jpn mka quavonlimabpembrolizumab mk gefapixant us firstline locally advanced metastatic urothelial cancer renal cell april pneumococcal vaccine adult keynotea eu jpn mk v us highrisk locally advanced cervical cancer endometrial december pulmonary arterial hypertension keynotea eu nonsmallcell lung november mk sotatercept us eu firstline negative locally advanced unresectable mk keytruda metastatic gastric cancer cutaneous squamous cell august eu keynote jpn hepatocellular may eu firstline locally advanced unresectable metastatic biliary mesothelioma may tract cancer ovarian december keynote jpn smallcell lung may mka pembrolizumabhyaluronidase subcutaneous nonsmallcell lung february mk bomedemstat myeloproliferative disorders mk welireg mka favezelimabpembrolizumab previously treated advanced renal cell carcinoma colorectal november lightspark eu hematological malignancies october mk prostate december mk lynparza nonsmallcell lung june smallcell lung december mka vibostolimabpembrolizumab melanoma january nonsmallcell lung april smallcell lung march mk lenvima esophageal july footnotes gastric december v developed collaboration ne ol na n mm aa cju el ly l l u n g december developed combination keytruda hiv infection developed monotherapy andor combination keytruda hym pek r c h lea td eo rora lv emirin iaeislatravir february fda clinical hold mk august fda partial clinical hold higher doses used current clinical trials pne vu c jo uc lyc l v c c ein ue adult phase b development costs cofunded respiratory syncytial virus available us emergency use authorization mk clesrovimab november ulcerative colitis december fda issued crl nda gefapixant merck reviewing fdas feedback mk tulisokibart october determine next steps human capital december company approximately employees worldwide approximately employed us including puerto rico additionally approximately thirdparty contractors globally approximately companys employees fulltime employees globally women comprise employees us individuals underrepresented ethnic groups comprise workforce company defines workforce employees women comprise members board directors additionally companys senior management team made women approximately companys employees represented various collective bargaining groups companys voluntary turnover rate approximately respectively company recognizes employees critical meet needs patients customers ability excel depends integrity skill diversity employees third party contractors include companys temporary workers independent contractors freelancers viewed fulltime equivalent employees exclude outsourced service providers talent acquisition company uses comprehensive approach ensure recruiting retention leadership development goals systematically executed throughout company hires talented leaders achieve improved gender parity representation across dimensions diversity company provides training table contents managers external recruiting organizations strategies mitigate unconscious bias candidate selection hiring process addition company utilizes comprehensive communications strategy employee branding marketing outreach social media strategic alliance partnerships reach broad pool talent critical business areas company hired approximately employees across globe various channels including companys external career site direct passive candidate sourcing diversity partnerships employee referrals universities external sources global diversity inclusion diversity inclusion fundamental companys success core future innovation company fosters globally diverse inclusive workforce employees creating environment belonging engagement equity empowerment company proactive intentional diversity hiring development programs advance talent company creates competitive advantages leveraging diversity inclusion accelerate business performance includes fostering global supplier diversity integrating diversity inclusion companys commercialization strategies leveraging employee insights improve performance addition efforts company ten employee business resource groups provide opportunities employees take active part contributing companys inclusive culture work talent acquisition development business customer insights social community outreach gender ethnicity data women board directors women senior management roles women management roles women workforce new hires women members underrepresented ethnic groups board directors members underrepresented ethnic groups senior management roles us members underrepresented ethnic groups management roles us members underrepresented ethnic groups workforce us new hires members underrepresented ethnic groups us selfidentified company senior management role defined individual holding either vice president senior vice president title management role defined managers direct reports compensation benefits company provides valuable suite compensation benefits programs reflect commitment attract retain motivate talent support employees families every stage life company continuously monitors adjusts compensation benefit programs ensure competitive contemporary helpful engaging support strategic imperatives diversity inclusion equity flexibility quality security affordability example company regularly monitors evaluates pay practices policies ensure paying employees equitably across genders races ethnicities company offers personal health care concierge service assist us employees participating company medical plan health care needs aligned business support cancer care strategy company provides enhanced cancer screening benefits cash incentives immediate access leading cancer center excellence us employees high value cancer support resources eg caregiving mental health employees families globally company implemented minimum standard weeks paid parental leave inclusively applies parents us companys benefits rank top quartile fortune companies aon benefits index company included seramount previously working mother best companies ranking consecutive years named top ten best company moms table contents employee wellbeing company committed helping employees families improve health wellbeing whether physical mental financial social companys programs ensure quality competitive value protection significant financial hardship access tools resources support employees families stages career lives earning company accolades business group healths best employers excellence health wellbeing ceo roundtable cancers global gold standard employer accreditation company fosters array flexible work arrangements includes flextime summer hours remote work telework job sharing parttime work help employees succeed personally well professionally part companys overall culture wellbeing also offers onsite services employees thrive example us include onsite health care professionals many major sites cafeterias committed healthy menu offerings onsite childcare onsite gyms convenient option bank two employee credit unions engaging employees company strives foster employee engagement promoting safe positive diverse inclusive work environment provides numerous opportunities twoway communication employees companys key programs initiatives include promoting global employee engagement surveys ongoing pulse checks organization interim feedback specific topics fostering professional networking collaboration identifying providing opportunities volunteering establishing positive cooperative business relations designated employee representatives talent management development company pursues goal becoming worlds premier researchbased biopharmaceutical company consistent focus importance continuously developing diverse talented people company committed talent growth allowing employees move fluidly across organization unlocking environment allows shape career pathways via nonlinear inclusive opportunities experience mercks current talent management system supports companywide performance management leadership development talent reviews succession planning annual performance reviews help professional development companys employees ensure companys workforce aligned companys objectives company seeks continuously build skills capabilities workforce accelerate talent improve performance mitigate risk relevant continuous learning experiences includes limited building leadership management skills well providing technical functional training employees environmental matters environmental sustainability company committed enabling safe sustainable healthy future strives strong environmental steward evolving efforts face changing world companys environmental sustainability strategy three focus areas driving operational efficiency designing new products minimize environmental impact reducing impacts companys upstream downstream value chain company ensures ongoing commitment areas thoughtful governance companys efforts area overseen environmental health safety ehs council companys ehs council crossfunctional body leadership representation area companys business including toplevel executives ehs council provides enterprise leadership sponsorship companys environmental sustainability strategy monitors progress towards companys public targets influences decisions environmental sustainability strategy implementation increasing visibility transparency internally business executive team board directors addition companys environmental sustainability implementation steering committee also comprising toplevel executives oversees progress initiatives enterprise level provides support guidance implementation plans resourcing companys environmental sustainability strategy globally steering committee informed leaders environmental sustainability center excellence coe global energy sustainability coe energy procurement coe develop companys goals alignment stakeholder expectations track progress develop provide continuous improvement plans achieve sustain companys public commitments table contents merck believes climate change could present risks business discussed detail item risk factors headings climate change legal regulatory market measures address climate change may negatively affect companys business results operations cash flows prospects environmental social governance esg matters may impact companys business reputation potential impacts climate change companys business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy usage water use greenhouse gas emissions company adopted set climate goals help position succeed increasingly resourceconstrained world goals developed align latest climate science address rising expectations companys customers investors external stakeholders employees regarding environmental impact operations supply chain companys climate goals include reducing scope operational greenhouse gas emissions baseline achieving carbon neutrality scope greenhouse emissions across operations sourcing purchased electricity renewable sources reducing scope greenhouse gas emissions baseline company also committed sciencebased targets initiative sbti set netzero target greenhouse gas emissions across global operations scopes environmental sustainability initiatives company include playbooks sustainable environment companys local sites crucial achieving ambitious environmental sustainability goals company continues launch tools assist particularly climate waste targets company launched low carbon transition playbook lctp common platform includes gap assessment help companys global sites evaluate maturity energy programs help create short longterm plans reduce sites carbon intensity build toward lowcarbon future based learnings use company issued lctp capability facilitate knowledge sharing across sites company also created waste diversion playbook takes similar approach guide sites developing roadmap companys shared goals waste diversion including local wastediversion strategies environmentally responsible procurement practices tools aid reporting tracking projects support achievements towards meeting companys corporate targets realizing benefits green sustainable science company believes meeting environmental sustainability goals intrinsically linked creation innovative costefficient manufacturing processes low environmental impact company aims develop efficient sustainable processes product launch goal minimizing material use waste commercial manufacturing company utilizes innovative greenbydesign development strategy goal progress initial early clinical supply route fully optimized sustainable commercial manufacturing process fourth year row company received peter j dunn award green chemistry engineering impact award given american chemical society recognition outstanding implementation novel green chemistry pharmaceutical industry partnering progress across companys value chain company engaging strategic suppliers identify ways reduce greenhouse gas emissions supply chain waste diversion company continuously evaluates sites waste disposal methods gain better understanding network changes therein well identify risks opportunities value chain based evaluation company implemented programs divert nonhazardous landfill waste two highest landfillgenerating sites company remains committed public waste diversion goals companys global operational waste sent landfills incinerators without energy recovery sites send zero waste landfills water shared resource water key input companys manufacturing operations company assesses water risk throughout network standard business practice companys priority waterstress risk sites conservation plans place actively working water use reduction recycling improvement projects projects consistent companys ongoing commitment achieving stated target maintaining global water use levels companys sites employing various technologies techniques aimed reducing water footprint improving operational performance companys table contents continued endorsement united nations ceo water mandate enables continued alignment companys water program mandates principles directly companys operations company continued identify partnerships help advance water stewardship priorities areas operates company continues review explore opportunities environmental strategy evaluate potential impacts commitments management believe expenditures related initiatives material adverse effect companys financial condition results operations liquidity capital resources year environmental regulation remediation company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year geographic area information companys operations outside us conducted primarily subsidiaries sales worldwide subsidiaries outside us percentage total company sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time available information companys internet website address merckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec address website secgov addition company provide without charge copy annual report including financial statements schedules upon written request shareholder office secretary merck co inc east lincoln avenue rahway nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomcompanyoverviewleadershipboardofdirectors information available print shareholder requests company companys impact report provides enhanced esg disclosures available companys website wwwmerckcomcompanyoverviewesgesgresources information companys impact report incorporated reference item risk factors summary risk factors company subject number risks realized could materially adversely affect business results operations cash flow financial condition prospects following summary principal risk factors facing company table contents company dependent patent rights patent rights invalidated circumvented business could materially adversely affected companys products lose market exclusivity company generally experiences significant rapid loss sales products key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequently company may able replace sales successful products lose patent protection companys success dependent successful development marketing new products subject substantial risks company faces continued pricing pressure respect products unfavorable uncertain economic conditions together costreduction measures taken certain governments could negatively affect companys operating results company faces intense competition lower cost generic products competitors products company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition climate change legal regulatory market measures address climate change may negatively affect companys business results operations cash flows prospects environmental social governance esg matters may impact companys business reputation failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products company may experience difficulties delays manufacturing certain products including vaccines company may able realize expected benefits investments emerging markets company exposed market risk fluctuations currency exchange rates interest rates pharmaceutical products develop unexpected safety efficacy concerns reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business negative events animal health industry could material adverse effect future results operations financial condition company animal health business biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition health care industry us continue subject increasing regulation political action companys products including products development marketed unless company obtains maintains regulatory approval developments following regulatory approval may adversely affect sales companys products company subject variety us international laws regulations table contents company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition adverse outcomes current future legal matters could negatively affect mercks business product liability insurance products may limited cost prohibitive unavailable company increasingly dependent sophisticated software applications computing infrastructure company continues target cyberattacks could lead disruption worldwide operations including manufacturing research sales operations social media mobile messaging platforms present risks challenges list exhaustive company faces additional challenges risks investors carefully consider information set forth including following risk factors deciding invest companys securities risk factors risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations cash flow prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results risks related companys business company dependent patent rights patent rights invalidated circumvented business could materially adversely affected patent protection considered aggregate material importance companys marketing human health animal health products us major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business successfully assert defend patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company asserts defends patents within outside us including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic biosimilar pharmaceutical products time time file abbreviated ndas blas fda seeking market genericbiosimilar forms companys products prior expiration relevant patents owned licensed company company normally responds asserting one patents lawsuit alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation us certain foreign markets relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company launched commercially successful products replace lost sales addition products measured fair value capitalized connection acquisitions experience difficulties market negatively affect product cash flows company may recognize material noncash impairment charges respect value products table contents chart listing key patent protection certain companys marketed products us patent protection candidates phase clinical development set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial condition prospects company lost market exclusivity bridion eu company experienced substantial decline bridion sales markets bridion lost market exclusivity japan january lose market exclusivity us subject patent litigation discussed company expects sales markets decline substantially thereafter addition company expects lose market exclusivity us keytruda company anticipates sales keytruda us decline substantially thereafter key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys ability generate profits operating cash flow depends largely upon continued profitability companys key products keytruda gardasilgardasil lynparza bravecto bridion companys oncology portfolio led keytruda vaccines portfolio led gardasilgardasil represented substantially companys revenue growth particular aggregate sales keytruda gardasilgardasil represented companys total sales result companys dependence key products event adversely affects products markets products could significant adverse impact results operations financial condition events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequently company may able replace sales successful products lose patent protection order remain competitive company like major pharmaceutical companies must continue launch new products expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs vaccines result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing table contents company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial condition prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications anticipated labeling uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions certain collaborations failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial condition prospects company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins us include us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca ira ii practices managed care groups institutional governmental purchasers iii state activities aimed increasing price transparency including new laws noted item competition health care environment changes health care system enacted part health care reform us well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures noted item competition health care environment hhs included januvia first year iras price setting program absent legislative court intervention result government set price becoming effective january furthermore company anticipates hhs include keytruda subsequent selection products undergo ira price setting price likely effective early addition us larger customers received higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company annually posts website pricing transparency report us report provides companys average annual list price net price increases across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns outside us numerous major markets including eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government table contents decision making budgetary actions respect products japan pharmaceutical industry subject governmentmandated annual price reductions pharmaceutical products certain vaccines furthermore japanese government order repricing specific products determines use product exceed certain thresholds defined applicable repricing rules company expects pricing pressures continue future unfavorable uncertain economic conditions together costreduction measures taken certain governments could negatively affect companys operating results companys business may adversely affected local global economic conditions including respect inflation interest rates costs raw materials packaging uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial condition prospects discussed item competition health care environment global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys sales performance negatively affected costreduction measures taken governments third parties lower health care costs company anticipates actions additional actions future negatively affect sales profits credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company faces intense competition lower cost generic products competitors products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker us eu us eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time us countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales business cash flow results operations financial condition prospects also companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use better insurance coverage reimbursement levels effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial condition prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products table contents company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition extent companys operations outside us significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions us governments foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease events like ongoing war russia ukraine rising conflict middle east could result material adverse effects macroeconomic conditions currency exchange rates financial markets may adversely affect companys business results operations financial condition climate change legal regulatory market measures address climate change may negatively affect companys business results operations cash flows prospects company believes climate change potential negatively affect business results operations cash flow prospects company exposed physical risks extreme weather conditions inland flooding rising sea levels risks transitioning lowcarbon economy additional legal regulatory requirements changes technology market risk reputational risk social human effects population dislocations harm health wellbeing associated climate change risks either acute shortterm chronic longterm adverse impacts climate change include increased frequency severity natural disasters extreme weather events hurricanes tornados wildfires exacerbated drought flooding extreme heat extreme weather inland flooding sealevel rise pose physical risks companys facilities well suppliers risks include losses incurred result physical damage facilities loss spoilage inventory business interruption caused natural disasters extreme weather events potential physical impacts due climate change include reduced access highquality water certain regions loss biodiversity could impact future product development risks could disrupt companys operations supply chain may result increased costs new legal regulatory requirements may enacted prevent mitigate adapt implications changing climate effects environment regulations may differ across jurisdictions could result company subject new expanded carbon pricing taxes increased compliance costs restrictions greenhouse gas emissions investment new technologies increased greenhouse gas emission disclosure including costs resulting mandatory voluntary reporting diligence disclosure transparency recurring investments data gathering reporting systems upgrades facilities meet new building codes redesign utility systems could increase companys operating costs including cost electricity energy used company companys supply chain would likely subject transitional risks would likely pass along increased costs company may affect companys ability procure raw materials supplies required operation companys business quantities levels required table contents environmental social governance esg matters may impact companys business reputation governmental authorities nongovernmental organizations customers investors external stakeholders employees increasingly sensitive esg concerns diversity inclusion climate change water use recyclability recoverability packaging plastic waste focus esg concerns may lead new requirements could result increased costs associated developing manufacturing distributing companys products related reporting obligations companys ability compete could also affected changing customer preferences requirements growing demand validated net zero greenhouse gas emission targets environmentally friendly products packaging supplier practices failure meet customer expectations demand company strives improve esg performance set certain esg goals initiatives company risks negative shareholder reaction including proxy advisory services well damage brand reputation inability attract retain employee talent company fails meet goals initiatives otherwise act responsibly company perceived acting responsibly key esg areas including equitable access medicines vaccines product quality safety diversity inclusion environmental stewardship reduction greenhouse gas emissions support local communities corporate governance transparency addressing human capital factors companys operations responding esg considerations implementation companys esg goals initiatives involves risks uncertainties requires investments depends part thirdparty performance data outside companys control addition stakeholders may disagree companys esg goals initiatives company meet evolving varied esg expectations investors customers stakeholders company could experience reduced demand products loss customers negative impacts companys business results operations addition company subject expanding esg mandatory voluntary reporting diligence disclosure requirements including eus corporate sustainability reporting directive csrd potentially secs proposed climaterelated reporting requirements recently enacted legislation california requiring reporting greenhouse gas emissions climate risk similar regulatory requirements jurisdictions evolving regulatory requirements likely result increased costs complexities compliance order collect measure report relevant esgrelated information failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry us internationally intense company sure able attract retain quality personnel costs materially increase company may experience difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines example company issued product recall zerbaxa following identification product sterility issues company voluntarily recalled certain batches vaxneuvance us due instances syringe breakage company may future experience difficulties delays manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including supply chain delays shortages raw materials changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply previously disclosed company working reduce level nitrosamines sitagliptincontaining medicines januvia company made significant progress reducing level nitrosamines consistently releasing product major markets expected comply health authorities longterm limit however difficulties reducing levels achieving timely regulatory approvals required changes could result product shortages addition company could experience difficulties delays manufacturing products caused natural disasters hurricanes manufacturing difficulties result product shortages leading lost sales reputational harm company table contents company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company operate successfully emerging markets must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets may affect ability realize continued growth may also increase companys risk exposure addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business outside us increased accordingly addition commercial operations company significant research manufacturing operations china including working chinese entities wuxi apptech co ltd geopolitical tensions increase disrupt companys operations china disruption could result material adverse effect companys product development sales business cash flow results operations financial condition prospects also continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls noted item competition health care environment pricing pressure china increased chinese government taking steps reduce costs including implementing health care reform led acceleration generic substitution available mechanism drugs added nrdl evolves inclusion may require price negotiation could impact outlook market selected brands new nrdl recently completed new entries averaged price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution governments vbp program government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered last five rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward reasons sales within emerging markets carry significant risks however time macroeconomic growth selected emerging markets expected lead significant increased health care spending countries access innovative medicines patients failure maintain companys presence emerging markets could therefore material adverse effect companys business cash flow results operations financial condition prospects company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter business development transactions borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse changes fluctuations currency exchange rates interest rates inflation could negatively affect companys business cash flow results operations financial condition prospects example argentina currently experiencing hyperinflation affecting companys operations market order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions table contents reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business company depends third parties including suppliers distributors alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could material adverse effect future results operations financial condition company animal health business future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals african swine fever avian influenza could lead widespread death precautionary destruction well reduced consumption demand animals could adversely affect companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt manufacture animal health products sites force company incur substantial expenses procuring raw materials products elsewhere risks specific animal health include epidemics pandemics affecting livestock government procurement pricing practices weather global agribusiness economic events addition sales bravecto billion represented companys animal health segment sales negative event respect bravecto could material adverse effect companys animal health sales animal health segment companys business becomes significant impact events future results operations could also become significant biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long complex expensive uncertain process unique risks uncertainties related biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions us eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example us bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial human vaccine lot manufacturing biologics vaccines especially large quantities complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency biologics vaccines changes biologics vaccines costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines table contents use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs risks relating government regulation legal proceedings health care industry us continue subject increasing regulation political action discussed item competition health care environment company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures congress passed ira makes significant changes drugs covered paid medicare program including creation financial penalties drugs whose prices rise faster rate inflation redesign medicare part program require manufacturers bear liability certain drug benefits government pricesetting certain medicare part drugs starting medicare part b drugs starting noted item competition health care environment hhs included januvia first year iras price setting program absent legislative court intervention result government set price becoming effective january furthermore company anticipates hhs include keytruda subsequent selection products undergo ira price setting price likely effective early addition congress passed american rescue plan act included provision eliminates statutory cap rebates drug manufacturers pay medicaid beginning january rebates act discount list price eliminating cap means manufacturer discounts paid medicaid increase prior change manufacturers required pay average manufacturer price amp rebates state medicaid programs medicaidcovered drugs result provision beginning manufacturers may pay state medicaid programs rebates received sales particular products change presents risk merck drugs high medicaid utilization rebate exposure amp us biden administration congress continue discuss legislation designed control health care costs including cost drugs company predict additional future changes health care industry general pharmaceutical industry particular occur however changes could material adverse effect companys business cash flow results operations financial condition prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities us including fda foreign regulatory authorities including eu japan china us fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals vaccines cases fda requirements increased amount time resources necessary develop new products bring market us regulation outside us also primarily focused drug safety effectiveness many cases reduction cost drugs fda foreign regulatory authorities including eu japan china substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals limited circumstances may include authorizations emergency use jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling products jurisdiction realizing sales table contents developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following results postapproval phase trials studies rereview products already marketed recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy quality labeling changes scrutiny advertising promotion withdrawal indications granted pursuant accelerated approvals past clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pmda chinas nmpa increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities addition dissemination promotional materials evolving digital channels serves increase visibility scrutiny marketplace company subject variety us international laws regulations company currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business cash flow results operations financial condition prospects company laws regulations include additional health care reform initiatives us countries including additional mandatory discounts fees ii us foreign corrupt practices act fcpa antibribery corruption laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement access marketing within across jurisdictions iv changes intellectual property laws v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu us china vii legislative mandates preferences local manufacturing pharmaceutical vaccine products viii emerging new global regulatory requirements reporting payments value transfers health care professionals ix environmental regulations eus csrd x potential impact importation restrictions embargoes trade sanctions legislative andor regulatory changes company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns routinely examined various tax authorities connection organization economic cooperation development oecd base erosion profit shifting project companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned table contents countries company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may negatively affected changes tax laws new tax laws affecting example tax rates andor revised tax law interpretations domestic foreign jurisdictions including among others potential changes existing us tax law current us presidential administration congress well changes tax law resulting implementation oecds two pillar solution reform international tax landscape company taken position based opinions tax counsel distribution organon common stock connection spinoff qualifies transaction taxfree us federal income tax purposes facts assumptions representations undertakings company organon regarding past future conduct respective businesses matters incorrect otherwise satisfied spin may qualify taxfree treatment could result significant us federal income tax liabilities company shareholders adverse outcomes current future legal matters could negatively affect mercks business current future litigation claims proceedings government investigations could preclude delay commercialization mercks products could adversely affect mercks business results operations cash flow prospects financial condition legal matters may include limited intellectual property disputes ii adverse decisions litigation including product safety liability consumer protection commercial cases iii anti bribery regulations fcpa including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v product pricing promotional matters vi lawsuits claims administrative proceedings asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws regulations vii environmental health safety sustainability matters including regulatory actions response climate change viii tax liabilities resulting assessments tax authorities see item financial statements supplementary data note contingencies environmental liabilities information companys legal matters product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost insurance increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company self insures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise risks related technology company increasingly dependent sophisticated software applications computing infrastructure company continues target cyberattacks could lead disruption worldwide operations including manufacturing research sales operations company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure cloud service providers collectively systems conduct critical operations financial reporting certain systems managed hosted provided used third parties assist conducting companys business disruption degradation manipulation systems intentional accidental means companys employees third parties authorized access unauthorized third parties could adversely affect key business processes cyberattacks companys systems thirdparty providers systems cloudbased systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise replace outmoded technology improve efficacy efficiency business processes including data table contents acquisition use create new risks addition companys animal health business sells technology products deployed could potentially compromised third party cause disruption internally externally although aggregate impact cyberattacks network disruptions companys operations financial condition material date company continues target events nature expects continue company monitors data information technology personnel usage company systems identify attempt reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems efforts thirdparty providers protect systems successful preventing disruptions companys operations including manufacturing research sales operations disruptions past could future result loss revenue loss critical sensitive information companys companys thirdparty providers databases systems past could future also result financial legal business reputational harm company substantial remediation costs companys growing use artificial intelligence ai systems automate processes analyze data support decisionmaking poses inherent risks flaws biases malfunctions systems could lead operational disruptions data loss erroneous decisionmaking impacting companys business operations financial condition reputation ethical legal challenges may arise including biases discrimination ai outcomes non compliance data protection regulations lack transparency furthermore deployment ai systems could expose company increased cybersecurity threats data breaches unauthorized access leading financial losses legal liabilities reputational damage company also faces competitive risks fails adopt ai machine learning technologies timely fashion social media mobile messaging platforms present risks challenges inappropriate andor unauthorized use certain social media mobile messaging channels could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking platforms could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media mobile messaging policies guide employees appropriate personal professional use platforms communication company processes place may completely secure protect information identifying new points entry new communication tools expand also presents new challenges cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs environmental sustainability initiatives one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage table contents process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures us abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys thirdparty providers information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda andor foreign regulatory authorities increased focus privacy issues countries around world including us eu china legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including laws majority states us requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item c cybersecurity companys cybersecurity measures primarily focused ensuring security protection information technology systems data companys information security program managed dedicated chief information security officer ciso whose group responsible leading enterprisewide cybersecurity risk management strategy policy standards architecture processes ciso worked cybersecurity national security fields years master science telecommunications computers served board member health information sharing analysis center years oversight information security program integrated companys overall enterprise risk management program ciso provides periodic reports audit committee audit committee board directors board full board well companys chief executive officer members senior management appropriate reports include updates companys cybersecurity risks threats status projects intended strengthen information security systems assessments information security program including remediation mitigation management identified vulnerabilities emerging threat landscape information security program regularly evaluated internal external consultants auditors table contents results reviews reported senior management audit committee comprised entirely independent directors oversight responsibility risks companys information security group monitors companys information systems prevent detect mitigate remediate cybersecurity incidents company uses tools techniques continually assess monitor manage mitigate cybersecurity threats systems manner consistent industry practice company engages key vendors industry participants intelligence law enforcement communities part continuing efforts obtain current threat intelligence collaborate security enhancements evaluate improve effectiveness information security program part program company conducts periodic tabletop exercises assess cybersecurity incident response processes company also maintains vendor management diligence oversight processes identify monitor potential risks cybersecurity threats attendant use thirdparty service providers additionally company monitors cybersecurity threat intelligence received key thirdparty service providers associated company event cybersecurity incident company process place whereby members security group alert ciso ciso alert appropriate levels management including incident assessment team well legal finance departments materiality event assessed furtherance fulfilling reporting requirements warranted senior management notify audit committee full board appropriate company continues target cyberattacks network disruptions date risks posed cybersecurity threats materially affected company business strategy results operations financial condition date report company aware material risks cybersecurity threats reasonably likely assurance company materially affected risks future information see item risk factors company increasingly dependent sophisticated software applications computing infrastructure company continues target cyberattacks could lead disruption worldwide operations including manufacturing research sales operations item properties companys corporate headquarters located rahway new jersey company also maintains divisional headquarters upper gwynedd pennsylvania principal us research facilities located rahway kenilworth new jersey west point pennsylvania boston cambridge massachusetts south san francisco california elkhorn nebraska animal health principal research facilities outside us located united kingdom switzerland china mercks manufacturing operations currently headquartered rahway new jersey company also production facilities human health products six locations us puerto rico outside us subsidiaries company owns interest manufacturing plants properties western europe africa asia company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained company believes plants manufacture products suitable intended purposes capacities projected capacities including previously disclosed capital expansion projects adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience robert davis chairman chief executive officer president since december chief executive officer president july december executive vice president global services chief financial officer april july sanat chattopadhyay executive vice president president merck manufacturing division since march richard r deluca jr executive vice president president merck animal health since september cristal downing executive vice president chief communications public affairs officer since august prior vice president medical devices global communications public affairs johnson johnson december august vice president financial communication johnson johnson january december chirfi guindo senior vice president chief marketing officer human health since july prior executive vice president head global product strategy commercialization biogen inc july july michael klobuchar executive vice president chief strategy officer since july senior vice president cfo merck rd head global portfolio alliance management january june dean li executive vice president president merck research laboratories since january senior vice president discovery sciences translational medicine merck research laboratories november january caroline litchfield executive vice president chief financial officer since april senior vice president corporate treasurer january march steven c mizell executive vice president chief human resources officer since october johannes j oosthuizen senior vice president president merck us human health since january senior vice president head global oncology commercial january december senior vice president president msd kk july december joseph romanelli senior vice president president msd international human health since july prior chief executive officer jixing pharmaceuticals july july president msd china december july dalton smart senior vice president finance global controller since december vice president assistant controller september december vice president internal audit march september david williams executive vice president chief information digital officer since august acting chief information digital officer december august vice president chief information officer merck animal health may december jennifer zachary executive vice president general counsel since april february company announced steven c mizell chief human resources officer retire company effective july february company announced ms betty larson join company assume role chief human resources officer effective beginning april time ms larson become mr mizell cease executive officer company mr mizell remain strategic advisory role company retirement name age offices business experience betty larson chief people officer ge healthcare since february executive vice president chief human resources officer becton dickinson june february table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities total number millions shares purchased total number average price part publicly approximate dollar value shares shares paid per announced plans may yet purchased period purchased share programs plans programs october october november november december december total shares purchased period made part plan approved board directors october purchase billion merck shares treasury table contents performance graph following graph assumes investment december reinvestment dividends companys common stock sp index composite peer group major us europeanbased pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company gilead sciences inc glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer group sp merck peer group sp compound annual growth rate peer group average calculated market cap weighted basis december performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act item reserved table contents item managements discussion analysis financial condition results operations following section generally discusses results yeartoyear comparisons discussion results yeartoyear comparisons included found part ii item managements discussion analysis financial condition results operations companys annual report fiscal year ended december filed february description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines including biologic therapies vaccines animal health products companys operations principally managed product basis include two operating segments pharmaceutical animal health reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers farmers pet owners june merck completed spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise historical results businesses contributed organon spinoff reflected discontinued operations companys consolidated financial statements date spinoff see note consolidated financial statements overview financial highlights change excluding change foreign excluding foreign millions except per share amounts change exchange change exchange sales net income continuing operations attributable merck co inc gaap nongaap earnings per common share assuming dilution continuing operations attributable merck co inc common shareholders gaap nongaap nongaap net income nongaap earnings per share eps exclude acquisition divestiturerelated costs restructuring costs income losses investments equity securities certain items mercks results prepared accordance generally accepted accounting principles us gaap discussion reconciliation gaap nongaap net income eps see nongaap income nongaap eps continuing operations executive summary mercks performance reflects strong execution scienceled strategy company benefited strong underlying demand across innovative portfolio made disciplined investments leverage table contents leading edge science advanced broad pipeline includes growing diversity across new therapeutic areas modalities additionally merck completed several strategic business development transactions returned capital shareholders primarily dividends worldwide sales billion increase compared excluding unfavorable effect foreign exchange sales increase primarily due growth oncology vaccines hospital acute care animal health partially offset declines virology driven lower sales covid medication lagevrio diabetes merck continues execute strategic business development opportunities augment robust internal pipeline compelling external science highlights activity include following entered global development commercialization agreement three daiichi sankyos deruxtecan dxd antibody drug conjugate adc candidates various stages clinical development treatment multiple solid tumors monotherapy andor combination treatments acquired prometheus biosciences inc prometheus clinicalstage biotechnology company pioneering precision medicine approach discovery development commercialization novel therapeutic companion diagnostic products treatment immunemediated diseases including ulcerative colitis crohns disease autoimmune conditions closed license collaboration agreement expanding companys relationship kelunbiotech pursuant merck gained exclusive rights research development manufacture commercialization five investigational preclinical adcs treatment cancer kelunbiotech retained rights certain licensed option adcs chinese mainland hong kong macau acquired imago biosciences inc imago clinicalstage biopharmaceutical company developing new medicines treatment myeloproliferative neoplasms bone marrow diseases company received regulatory approvals major markets including numerous regulatory approvals within oncology keytruda received approval additional indications us andor internationally monotherapy therapeutic areas nonsmallcell lung cancer nsclc primary mediastinal large bcell lymphoma pmbcl combination chemotherapy therapeutic areas biliary tract cancer gastric gastroesophageal junction gej adenocarcinoma nsclc well combination padcev enfortunab vedotinejfv advanced urothelial cancer lynparza developed collaboration astrazeneca plc astrazeneca received approvals us combination abiraterone prednisone prednisolone japan combination abiraterone prednisolone treatment certain adult patients brcamutated brcam metastatic castrationresistant prostate cancer mcrpc welireg approved supplemental indication us treatment adult patients advanced renal cell carcinoma rcc following programmed death receptor pd programmed deathligand pdl inhibitor vascular endothelial growth factor tyrosine kinase inhibitor vegftki additionally prevymis approved supplemental indication us eu prophylaxis prevention cytomegalovirus cmv disease certain adult kidney transplant recipients high risk addition recent regulatory approvals discussed company advanced latestage pipeline several regulatory submissions mk sotatercept novel investigational activin signaling inhibitor priority review us food drug administration fda review european medicines agency treatment adult patients pulmonary arterial hypertension pah table contents v investigational valent pneumococcal conjugate vaccine prevention invasive pneumococcal disease pneumococcal pneumonia adults also priority review fda mk patritumab deruxtecan adc evaluated treatment certain types nsclc priority review fda patritumab deruxtecan part collaboration daiichi sankyo additionally keytruda review us andor international markets supplemental indications treatment certain patients biliary tract cervical endometrial gastric nonsmallcell lung urothelial cancers welireg review eu treatment certain patients advanced rcc treatment von hippellindau disease company initiated phase studies across multiple asset classes including progression eight novel candidates company diversifying oncology portfolio executing strategy broadly based three strategic pillars immunooncology precision molecular targeting tissue targeting mercks phase oncology programs within pillars follows immunooncology keytruda therapeutic areas cutaneous squamous cell hepatocellular mesothelioma ovarian smallcell lung cancers mka coformulation quavonlimab mercks novel investigational antictla antibody pembrolizumab rcc mka subcutaneous coformulation pembrolizumab hyaluronidase certain types nsclc mka coformulation favezelimab mercks novel investigational antilag therapy pembrolizumab colorectal cancer hematological malignancies mka coformulation vibostolimab antitigit therapy pembrolizumab certain types melanoma nonsmallcell smallcell lung cancers v investigational individualized neoantigen therapy combination keytruda certain types melanoma nsclc developed collaboration moderna precision molecular targeting lynparza combination keytruda nonsmallcell lung smallcell lung cancers lenvima developed collaboration eisai co ltd eisai combination keytruda certain types esophageal gastric cancers mk nemtabrutinib oral reversible noncovalent brutons tyrosine kinase btk inhibitor hematological malignancies mk bomedemstat investigational orally available lysinespecific demethylase inhibitor myeloproliferative disorders mk investigational cytochrome p cypa inhibitor developed collaboration orion corporation orion mcrpc tissue targeting mk investigational trophoblast cellsurface antigen tropdirected adc developed collaboration kelunbiotech endometrial carcinoma certain types nsclc additionally company currently candidates phase clinical development several therapeutic areas including mk investigational oral proprotein convertase subtilisinkexin type pcsk inhibitor hypercholesterolemia mk clesrovimab human monoclonal antibody prevention respiratory syncytial virus rsv mk tulisokibart humanized monoclonal antibody directed tumor necrosis factorlike ligand target associated intestinal inflammation fibrosis ulcerative colitis table contents mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor combination doravirine treatment hiv infection partial clinical hold higher doses used current clinical trials mk lagevrio reflected phase development us remains investigational following emergency use authorization eua mercks capital allocation strategy continues prioritize investments business drive near longterm growth including investing opportunities address important unmet medical needs supporting companys commercial opportunities addition merck remains committed dividend continue pursue compelling external science technologies valueenhancing business development transactions research development expenses reflect higher charges business development transactions increased development spending particularly therapeutic areas oncology cardiovascular infectious diseases vaccines november mercks board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock company returned billion shareholders dividends billion share repurchases billion gaap nongaap eps negatively affected respectively charges certain upfront preapproval milestone payments related collaborations licensing agreements well charges related preapproval assets obtained transactions accounted asset acquisitions pricing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system enacted prior years part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys sales performance negatively affected costreduction measures taken governments third parties lower health care costs us congress passed inflation reduction act ira makes significant changes drugs covered paid medicare program including creation financial penalties drugs whose prices rise faster rate inflation redesign medicare part program require manufacturers bear liability certain drug benefits government pricesetting certain medicare part drugs starting medicare part b drugs starting august us department health human services hhs centers medicare medicaid services cms announced januvia included first year iras drug price negotiation program program pursuant iras program discussions government occurred continue government pricesetting becoming effective january company sued us government regarding iras program see note consolidated financial statements furthermore biden table contents administration congress continue discuss legislation designed control health care costs including cost drugs company anticipates actions additional actions future negatively affect sales profits operating results sales change change excluding foreign excluding foreign millions change exchange change exchange united states international total worldwide sales grew billion primarily due higher sales oncology franchise largely due strong growth keytruda welireg well increased alliance revenue lenvima lynparza also contributing revenue growth higher sales vaccines franchise primarily attributable growth combined sales gardasilgardasil ongoing launch vaxneuvance pediatric use higher sales hospital acute care products including prevymis bridion well higher sales animal health products also drove revenue growth sales growth largely offset lower sales virology franchise largely due lagevrio well isentressisentress hd lower sales diabetes franchise due januvia janumet lower sales pneumovax vaccine lower revenue thirdparty manufacturing arrangements also offset sales growth sales us grew billion primarily driven higher sales keytruda vaxneuvance bridion welireg revenue growth us partially offset lower sales lagevrio pneumovax janumet januvia lower revenue thirdparty manufacturing arrangements international sales declined primarily due lower sales lagevrio januvia janumet isentressisentress hd international sales decline largely offset higher combined sales gardasilgardasil well higher sales keytruda prevymis vaxneuvance international sales represented total sales respectively see note consolidated financial statements details sales companys products discussion performance select products franchises follows pharmaceutical segment oncology change change excluding foreign excluding foreign millions change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima welireg alliance revenue reblozyl alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note consolidated financial statements alliance revenue represents royalties also includes payment received related achievement regulatory approval milestone see note consolidated financial statements keytruda antipd therapy approved indications us including tumor types tumoragnostic indications similarly approved markets worldwide many indications keytruda clinical development program includes studies across broad range cancer types global sales keytruda grew primarily driven higher demand reflecting launch multiple new indications globally coupled continued uptake existing indications sales growth us reflects increased uptake across earlierstage indications including highrisk earlystage triplenegative breast cancer tnbc well certain types rcc melanoma higher demand across multiple approved table contents metastatic indications particular treatment certain types rcc nsclc tnbc head neck squamous cell carcinoma hnscc endometrial bladder cancers well higher pricing keytruda sales growth international markets reflects higher demand predominately tnbc rcc earlierstage indications well uptake hnscc rcc metastatic indications particularly europe latin america asia pacific region including japan summarized keytruda regulatory approvals received date date approval fda approval single agent adjuvant treatment following surgical resection platinumbased chemotherapy adult patients january stage ib ta cm ii iiia nsclc based keynote trial fda full approval treatment adult pediatric patients unresectable metastatic microsatellite instabilityhigh msih mismatch repair deficient dmmr solid tumors progressed following prior treatment satisfactory alternative march treatment options conversion accelerated full regular approval based keynote keynote keynote trials fda accelerated approval combination padcev enfortumab vedotinejfv treatment adult patients locally advanced april metastatic urothelial carcinoma eligible cisplatincontaining chemotherapy based keynote trial dose escalation cohort cohort cohort k conducted collaboration seagen pfizer inc pfizer astellas june japans ministry health labor welfare mhlw approval treatment patients relapsed refractory pmbcl based keynote keynotea studies european commission ec approval combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy august firstline treatment locally advanced unresectable metastatic human epidermal growth factor receptor herpositive gastric gej adenocarcinoma adults whose tumors express pdl based keynote trial chinas national medical products administration nmpa approval monotherapy treatment adult patients advanced unresectable metastatic msih dmmr solid tumors including patients colorectal cancer progressed following treatment september fluoropyrimidine oxaliplatin irinotecan solid tumors progressed following prior therapy satisfactory alternative treatment options based keynote keynote trials ec approval monotherapy adjuvant treatment adults nsclc high risk recurrence following complete october resection platinumbased chemotherapy based keynote trial fda approval treatment patients resectable tumors cm node positive nsclc combination platinum october containing chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery based keynote trial fda full approval treatment adult pediatric patients recurrent locally advanced metastatic merkel cell carcinoma october conversion accelerated full regular approval based keynote keynote trials fda approval combination gemcitabine cisplatin treatment patients locally advanced unresectable metastatic october biliary tract cancer based keynote trial fda approval combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment adults locally november advanced unresectable metastatic hernegative gastric gej adenocarcinoma based keynote trial fda full approval combination padcev enfortumab vedotinejfv adc treatment adult patients locally advanced december metastatic urothelial cancer conversion accelerated full regular approval based keynotea trial conducted collaboration seagen pfizer astellas ec approval combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment locally advanced december unresectable metastatic hernegative gastric gej adenocarcinoma adults whose tumors express pdl based keynote trial ec approval combination gemcitabine cisplatin firstline treatment locally advanced unresectable metastatic biliary december tract carcinoma adults based keynote trial table contents chinas nmpa approval combination fluoropyrimidine platinumcontaining chemotherapy firstline treatment patients december locally advanced unresectable metastatic hernegative gastric gej adenocarcinoma based keynote trial fda approval combination chemoradiotherapy treatment patients figo international federation gynecology january obstetrics stage iiiiva cervical cancer based keynotea trial fda full approval treatment patients hepatocellular carcinoma hcc secondary hepatitis b received prior january systemic therapy pdpdl containing regimen conversion accelerated full regular approval based keynote trial chinas nmpa approval combination gemcitabine cisplatin firstline treatment patients locally advanced february metastatic biliary tract carcinoma based keynote trial company party certain thirdparty license agreements pursuant company pays royalties sales keytruda terms significant agreements merck paid royalty worldwide sales keytruda december one third party royalty decline terminate thereafter company pays additional royalty worldwide sales keytruda another third party termination date varies country royalty expire us september varying dates major european markets second half royalties included cost sales lynparza oral poly adpribose polymerase parp inhibitor developed part collaboration astrazeneca see note consolidated financial statements lynparza approved treatment certain types advanced recurrent ovarian early metastatic breast metastatic pancreatic metastatic castrationresistant prostate cancers alliance revenue related lynparza grew largely due higher pricing us well higher demand several international markets lynparza received following regulatory approvals summarized date approval may fda approval combination abiraterone prednisone prednisolone treatment adult patients deleterious suspected deleterious brcam mcrpc based propel trial august japans mhlw approval combination abiraterone prednisolone treatment adult patients brcam mcrpc distant metastasis based propel trial lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai see note consolidated financial statements lenvima approved treatment certain types thyroid cancer rcc hcc combination everolimus certain patients advanced rcc combination keytruda certain patients advanced endometrial carcinoma advanced rcc alliance revenue related lenvima grew reflecting higher demand pricing us higher demand europe partially offset lower demand china sales welireg treatment adult patients certain von hippellindau diseaseassociated tumors certain adult patients previously treated advanced rcc increased due continued uptake us following launch december fda approved supplemental new drug application nda welireg treatment adult patients advanced rcc following pd pdl inhibitor vegftki based litespark clinical trial reblozyl firstinclass erythroid maturation recombinant fusion protein obtained part mercks november acquisition acceleron pharma inc acceleron commercialized global collaboration bristol myers squibb company bms see note consolidated financial statements reblozyl approved treatment anemia certain rare blood disorders alliance revenue related collaboration consists royalties also includes receipt regulatory approval milestone payment million alliance revenue increased due strong underlying sales performance partially offset receipt regulatory approval milestone noted table contents vaccines change change excluding foreign excluding foreign millions change exchange change exchange gardasilgardasil proquad mmr ii varivax vaxneuvance pneumovax combined worldwide sales gardasil gardasil vaccines help prevent certain cancers diseases caused certain types human papillomavirus hpv grew driven strong demand outside us particularly china due part continued uptake expanded indication gardasil girls women years age sales gardasil us increased slightly due higher pricing demand largely offset public sector buying patterns company party certain thirdparty license agreements pursuant company pays royalties sales gardasilgardasil terms significant agreements merck pays royalty sales gardasilgardasil us one third party royalty expires december merck paid additional royalty worldwide sales gardasilgardasil another third party expired december royalties included cost sales global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella grew primarily due higher pricing us partially offset lower demand europe worldwide sales mmr ii vaccine help protect measles mumps rubella grew primarily due higher demand certain international markets higher pricing us partially offset lower demand us global sales varivax vaccine help prevent chickenpox varicella grew primarily attributable higher pricing demand us well higher demand asia pacific region partially offset lower demand latin america worldwide sales vaxneuvance vaccine help protect invasive pneumococcal disease increased million primarily due continued uptake pediatric indication us launches european markets vaxneuvance currently launched markets additional launches planned merck party thirdparty license agreement pursuant company pays royalty net sales vaxneuvance royalty decline net sales royalties included cost sales worldwide sales pneumovax vaccine help prevent pneumococcal disease declined due lower demand us market continues shift toward newer adult pneumococcal conjugate vaccines following changes recommendations us centers disease control preventions advisory committee immunization practices company expects decline us sales pneumovax continue pneumovax us sales decline partially offset higher demand several international markets hospital acute care change change excluding foreign excluding foreign millions change exchange change exchange bridion prevymis dificid global sales bridion reversal two types neuromuscular blocking agents used surgery grew reflecting higher demand us attributable part bridions increased share among neuromuscular blockade reversal agents well higher pricing partially offset generic competition table contents international markets particularly eu patent provided market exclusivity bridion eu expired july accordingly company experiencing sales declines bridion markets expects declines continue patent provided market exclusivity bridion japan expired january company anticipates sales bridion japan decline future periods worldwide sales prevymis medicine prophylaxis prevention cmv infection disease certain high risk adult recipients allogenic hematopoietic stem cell transplant prophylaxis cmv disease certain high risk adult recipients kidney transplant grew largely due higher demand us europe well continued uptake launch china june fda approved prevymis prophylaxis cmv disease certain adult kidney transplant recipients high risk following priority review based p clinical trial november ec also approved prevymis indication worldwide sales dificid treatment c difficileassociated diarrhea grew due higher demand us cardiovascular change change excluding foreign excluding foreign millions change exchange change exchange alliance revenue adempasverquvo adempas alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note consolidated financial statements adempas verquvo part worldwide collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators see note consolidated financial statements adempas approved treatment certain types pah chronic pulmonary hypertension verquvo approved reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults symptomatic chronic heart failure reduced ejection fraction verquvo approved us eu japan since approved several markets alliance revenue collaboration grew reflecting higher profit sharing reflects increased demand bayers marketing territories revenue also includes sales adempas verquvo mercks marketing territories sales adempas mercks marketing territories grew primarily reflecting higher demand virology change change excluding foreign excluding foreign millions change exchange change exchange lagevrio isentressisentress hd lagevrio investigational oral antiviral covid medicine developed collaboration ridgeback biotherapeutics lp ridgeback see note consolidated financial statements following initial authorizations certain markets fourth quarter lagevrio since received multiple additional authorizations sales lagevrio declined billion compared billion decline sales lagevrio primarily reflects sales lagevrio uk recur well lower sales us japan australia sales lagevrio us consisted sales us government november following authorization fda company began transition government supply commercial distribution us lagevrio eua april japans mhlw granted full approval lagevrio lagevrio previously granted special approval emergency japan december given company fulfilled government purchase supply commitments lagevrio well waning impacts covid pandemic company expects sales lagevrio decline worldwide combined sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection declined primarily due competitive pressure particularly us europe patent provided market exclusivity isentressisentress hd table contents eu expired july accordingly company experiencing sales declines isentressisentress hd markets result generic competition expects declines continue additionally company anticipates competitive pressure sales declines isentressisentress hd us continue immunology change change excluding foreign excluding foreign millions change exchange change exchange simponi remicade simponi remicade treatments certain inflammatory diseases company markets europe russia trkiye companys marketing rights respect products revert johnson johnson innovative medicine october diabetes change change excluding foreign excluding foreign millions change exchange change exchange januviajanumet worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes declined primarily reflecting ongoing impact loss exclusivity markets europe asia pacific region well canada coupled lower demand lower pricing us due competitive pressures key us patent januvia janumet claiming sitagliptin compound expired january result favorable court rulings settlement agreements related later expiring patent directed specific sitagliptin salt form products see note consolidated financial statements company expects januvia janumet lose market exclusivity us may janumet xr lose market exclusivity us july although nonautomatically substitutable form sitagliptin differs form companys sitagliptin products approved fda result competitive pressures company anticipates pricing volume declines januvia janumet us continue thereafter august us department hhs cms announced januvia included first year iras program pursuant iras program discussions government occurred continue government pricesetting becoming effective january company sued us government regarding iras program see note consolidated financial statements company lost market exclusivity januvia eu janumet european countries september exclusivity janumet lost european countries april accordingly company experiencing sales declines markets expects declines continue company lost market exclusivity januvia china launch generic equivalent product additional generic equivalent product launched impact sales modest several generic equivalents janumet approved china one launched december via settlement agreement company combined sales januvia janumet europe china us represented respectively total combined januvia janumet sales response request regulatory authority merck evaluated sitagliptincontaining products presence nitrosamines nitrosamines organic compounds found trace levels water food nitrosamines also result chemical reactions form drugs either due drugs manufacturing process chemical structure conditions drugs stored packaged company detected nitrosamine identified nitrosostg nttp batches sitagliptincontaining medicines company engaged major health authorities around world implemented additional quality controls ensure portfolio sitagliptincontaining products meet health authorities interim acceptable nttp limits continuing distribution product market company made significant progress reducing level nitrosamines sitagliptin containing medicines consistently releasing product major markets expected comply health authorities longterm limit throughout product shelflife company anticipate product shortages time table contents animal health segment change change excluding foreign excluding foreign millions change exchange change exchange livestock companion animal sales livestock products grew primarily due higher pricing well increased demand poultry swine products partially offset lower demand ruminant products sales companion animal products grew reflecting higher pricing partially offset lower demand sales bravecto line products billion increase compared excluding impact foreign exchange january ec approved injectable formulation bravecto dogs persistent killing fleas ticks months treatment february merck entered definitive agreement acquire aqua business elanco animal health incorporated billion cash acquisition expected completed mid subject approvals regulatory authorities customary closing conditions transaction accounted acquisition business see note consolidated financial statements additional information related transaction costs expenses millions change change cost sales selling general administrative research development restructuring costs income expense net cost sales cost sales billion billion cost sales includes million billion respectively related sales lagevrio developed collaboration ridgeback see note consolidated financial statements cost sales also includes amortization intangible assets recorded connection acquisitions collaborations licensing arrangements totaled billion amortization expense includes million million respectively cumulative catchup amortization related mercks collaborations eisai astrazeneca respectively see note consolidated financial statements also included cost sales expenses associated restructuring activities amounted million million primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared gross margin improvement primarily reflects favorable impacts product mix including lower lagevrio sales lower revenue thirdparty manufacturing arrangements lower gross margins lower manufacturingrelated costs partially offset unfavorable impact foreign exchange selling general administrative selling general administrative sga expenses billion increase compared increase primarily due higher administrative costs including compensation benefits increased promotional spending selling costs partially offset favorable effect foreign exchange lower acquisitionrelated costs table contents research development research development rd expenses billion compared billion increase primarily due higher charges business development activity including charges billion acquisition prometheus billion related formation collaboration daiichi sankyo billion acquisition imago compared charges million aggregate recorded related collaboration licensing agreements moderna orna therapeutics orion increase rd expenses also attributable higher development spending including recently acquired programs higher compensation benefit costs reflecting part increased headcount increase rd expenses partially offset lower intangible asset impairment charges rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities billion billion also included rd expenses animal health research costs upfront payments collaboration licensing agreements including charges daiichi sankyo moderna orna orion transactions noted charges transactions accounted asset acquisitions including charges prometheus imago noted costs incurred divisions support rd activities including depreciation production general administrative aggregate billion billion rd expenses also include impairment charges million related gefapixant billion largely related nemtabrutinib see note consolidated financial statements additional information related impairment charges company may recognize additional impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business combinations charges could material restructuring costs january company approved new restructuring program restructuring program intended continue optimization companys human health global manufacturing network future pipeline shifts new modalities also optimize animal health global manufacturing network improve supply reliability increase efficiency actions contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested remainder costs result cash outlays relating primarily facility shutdown costs company expects record charges approximately million related restructuring program company anticipates actions restructuring program result cumulative annual net cost savings approximately million end merck approved global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint actions restructuring program substantially complete restructuring costs million million include separation costs associated restructuring activities separation costs incurred associated actual headcount reductions well estimated expenses existing severance programs involuntary headcount reductions probable could reasonably estimated expenses restructuring costs include facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included cost sales selling general administrative expenses research development costs company recorded aggregate pretax costs related restructuring program activities million million related restructuring program million see note consolidated financial statements additional details income expense net income expense net million expense compared billion expense change primarily due net gains investments equity securities recorded compared net losses investments equity securities recorded well lower pension settlement costs partially offset million charge related settlements certain plaintiffs zetia antitrust litigation see note consolidated financial statements higher foreign exchange losses table contents details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits animal health segment profits income continuing operations taxes pharmaceutical segment profits comprised segment sales less standard costs well sga expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well sga rd expenses directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described rd expenses incurred mrl general administrative expenses directly incurred segments cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits costs related restructuring activities acquisition divestiturerelated costs including amortization intangible assets amortization purchase accounting adjustments intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing arrangements pharmaceutical segment profits grew primarily due higher sales partially offset higher administrative promotional costs well unfavorable effect foreign exchange animal health segment profits declined reflecting higher production costs higher inventory writeoffs increased administrative promotional costs well unfavorable effect foreign exchange taxes income effective income tax rates continuing operations high tax rate continuing operations includes percentage point combined unfavorable impact charges acquisitions prometheus imago tax benefits recognized daiichi sankyo collaboration charges reduced domestic pretax income approximately billion addition tax rate continuing operations reflects higher foreign taxes impact rd capitalization provision tax cuts jobs act tcja companys us global intangible lowtaxed income inclusion partially offset favorable mix income expense well higher foreign tax credits tax rate continuing operations reflects favorable mix income expense tax rate continuing operations also reflects favorable impact net unrealized losses investments equity securities intangible asset impairment charges taxed us tax rate items reduced domestic pretax income approximately billion many jurisdictions merck operates adopted global minimum tax provision organisation economic cooperation development oecd pillar effective tax years beginning january company anticipates minimal impact tax rate due accounting tax effects intercompany transactions company expects impact global minimum tax increase tax rate greater extent thereafter also event provision tcja requiring capitalization amortization rd expenses tax purposes repealed along lines recently proposed tax relief american families workers act company able realize benefit us rd expenses incurred expects material impact effective income tax rate table contents nongaap income nongaap eps continuing operations nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results since management uses nongaap measures assess performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs income losses investments equity securities certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps metric management uses nongaap measures internally planning forecasting purposes measure performance company along metrics addition annual employee compensation including senior managements compensation derived part using nongaap pretax income metric since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance gaap reconciliation gaap financial measures nongaap financial measures continuing operations follows millions except per share amounts income continuing operations taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs income loss investments equity securities net items charge zetia antitrust litigation settlements charges discontinuation covid development programs nongaap income continuing operations taxes taxes income continuing operations reported gaap estimated tax benefit excluded items net tax benefit settlement certain federal income tax matters nongaap taxes income continuing operations nongaap net income continuing operations less net income attributable noncontrolling interests reported gaap nongaap net income continuing operations attributable merck co inc eps assuming dilution continuing operations reported gaap eps difference nongaap eps assuming dilution continuing operations amounts include million billion million respectively intangible asset impairment charges estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments gaap nongaap eps negatively affected respectively charges certain upfront preapproval milestone payments related collaborations licensing agreements well charges related preapproval assets obtained transactions accounted asset acquisitions acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection acquisitions divestitures businesses amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges table contents expense income related changes estimated fair value measurement liabilities contingent consideration also excluded integration transaction certain costs associated acquisitions divestitures nongaap income nongaap eps also exclude amortization intangible assets related collaborations licensing arrangements restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs income losses investments equity securities nongaap income nongaap eps exclude realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds certain items nongaap income nongaap eps exclude certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charge related settlements certain plaintiffs zetia antitrust litigation see note consolidated financial statements charges related discontinuation covid development programs well net tax benefit related settlement certain federal income tax matters see note consolidated financial statements research development research pipeline company currently several candidates regulatory review us internationally well latestage clinical development chart reflecting companys current research pipeline february related discussion set forth item business research development acquisitions research collaborations licensing agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions summarized additional details included note note consolidated financial statements merck actively monitors landscape growth opportunities meet companys strategic criteria january merck entered agreement acquire harpoon therapeutics inc harpoon clinicalstage immunotherapy company developing novel class tcell engagers designed harness power bodys immune system treat patients suffering cancer diseases terms agreement merck acquire outstanding shares harpoon per share cash approximate total equity value million harpoons lead candidate hpn tcell engager targeting deltalike ligand dll inhibitory canonical notch ligand expressed high levels smallcell lung cancer neuroendocrine tumors hpn currently evaluated phase clinical trial monotherapy patients advanced cancers associated expression dll also combination atezolizumab patients certain types smallcell lung cancer closing acquisition expected first half subject certain conditions including approval merger harpoons stockholders expiration waiting period hartscottrodino antitrust improvements act customary conditions proposed transaction closes company anticipates accounted acquisition asset company expects record charge approximately million research development expenses upon closing approximately per share october merck daiichi sankyo entered global development commercialization agreement three daiichi sankyos deruxtecan dxd adc candidates patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk three potentially firstinclass dxd adcs various stages clinical development treatment multiple solid tumors monotherapy andor combination treatments companies jointly develop table contents potentially commercialize adc candidates worldwide except japan daiichi sankyo maintain exclusive rights daiichi sankyo solely responsible manufacturing supply terms agreement merck made upfront payments billion make two onetime continuation payments million daiichi sankyo additionally daiichi sankyo eligible receive future contingent salesbased milestone payments merck recorded aggregate pretax charge billion research development expenses per share related transaction june merck acquired prometheus clinicalstage biotechnology company pioneering precision medicine approach discovery development commercialization novel therapeutic companion diagnostic products treatment immunemediated diseases total consideration paid billion included billion costs settle sharebased equity awards including million settle unvested equity awards prometheus lead candidate tulisokibart mk formerly pra humanized monoclonal antibody directed tumor necrosis factorlike ligand target associated intestinal inflammation fibrosis tulisokibart developed treatment immunemediated diseases including ulcerative colitis crohns disease autoimmune conditions phase clinical trial evaluating tulisokibart ulcerative colitis commenced transaction accounted acquisition asset merck recorded net assets million well charge billion research development expenses per share related transaction future contingent payments associated acquisition february merck kelunbiotech closed license collaboration agreement expanding relationship merck gained exclusive rights research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelun biotech retained right research develop manufacture commercialize certain licensed option adcs chinese mainland hong kong macau merck made upfront payment million recorded research development expenses october merck notified kelun biotech terminating two seven candidates agreement kelunbiotech remains eligible receive future contingent milestone payments tiered royalties future net sales commercialized adc product also connection agreement merck invested million kelunbiotech shares january january merck acquired imago clinicalstage biopharmaceutical company developing new medicines treatment myeloproliferative neoplasms bone marrow diseases billion including payments settle sharebased equity awards also incurred approximately million transaction costs imagos lead candidate bomedemstat mk formerly img investigational orally available lysinespecific demethylase inhibitor currently evaluated multiple clinical trials treatment essential thrombocythemia myelofibrosis polycythemia vera addition indications phase clinical trial evaluating bomedemstat treatment certain patients essential thrombocythemia underway transaction accounted acquisition asset merck recorded net assets million well charge billion research development expenses related transaction future contingent payments associated acquisition acquired inprocess research development connection business combinations company records fair value inprocess research projects time acquisition yet reached technological feasibility december balance inprocess research development iprd billion primarily consisting mk sotatercept billion mk nemtabrutinib million sotatercept review us eu nemtabrutinib phase clinical development iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally iprd programs require additional clinical trial data previously anticipated programs fail abandoned development company recover fair value iprd recorded asset acquisition date circumstances occur companys future operating results could adversely affected company may recognize impairment charges could material company recorded iprd impairment charges within research development expenses million billion million respectively see note consolidated financial statements table contents additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval capital expenditures capital expenditures billion billion billion expenditures us billion billion billion company invested billion capital expenditures half related expenditures us company plans invest approximately billion capital projects billion relates investments us including expanding manufacturing capacity oncology vaccine animal health products depreciation expense billion billion billion billion billion billion related locations us total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development finance acquisitions external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operating activities continuing operations total debt decline working capital compared primarily reflects use cash investments fund business development activity partially offset strong operating performance cash proceeds issuance longterm debt cash provided operating activities continuing operations billion compared billion cash provided operating activities continuing operations reduced upfront milestone option payments related certain collaborations billion including payments related formation collaboration daiichi sankyo compared billion cash provided operating activities continuing operations also reduced payment million previously disclosed zetia antitrust settlement cash provided operating activities continuing operations continues companys primary source funds finance operating needs excess cash serving primary source funds finance business development transactions capital expenditures dividends paid shareholders treasury stock purchases mandatory change rd capitalization rules became effective tax years beginning december related tax cuts jobs act tcja increased amount taxes company pays us beginning cash used investing activities continuing operations billion compared billion higher use cash investing activities continuing operations primarily due acquisitions prometheus imago partially offset higher proceeds sales securities investments including proceeds sale seagen inc common stock lower capital expenditures lower purchases securities investments cash used financing activities continuing operations billion compared billion lower use cash financing activities continuing operations primarily due proceeds issuance debt see lower payments longterm debt see partially offset treasury stock purchases higher dividends paid shareholders lower proceeds exercise stock options may company issued billion principal amount senior unsecured notes company used portion billion net proceeds offering fund portion cash consideration paid acquisition prometheus including related fees expenses used remaining net proceeds general corporate purposes including repay commercial paper borrowings indebtedness upcoming maturities table contents december company issued billion principal amount senior unsecured notes merck used portion net proceeds offering general corporate purposes including repayment outstanding commercial paper borrowings including commercial paper borrowings connection mercks acquisition acceleron indebtedness also used allocated amount finance refinance whole part projects partnerships companys priority environmental social governance esg areas may companys billion notes matured accordance terms repaid companys billion notes companys billion notes matured accordance terms repaid companys billion notes companys billion notes matured accordance terms repaid company billion credit facility matures may facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility march company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date november mercks board directors increased quarterly dividend declaring quarterly dividend per share companys outstanding common stock first quarter paid january january board directors declared quarterly dividend per share companys outstanding common stock second quarter payable april mercks board directors authorized purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions company purchased billion approximately million shares common stock treasury program december companys remaining share repurchase authorization billion company purchase shares common stock program company purchased million common stock authorized share repurchase program company believes maintains conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations company expects foreseeable liquidity capital resource requirements met existing cash cash equivalents anticipated cash flows operations well commercial paper borrowings longterm borrowings needed merck believes sources financing adequate meet future requirements companys material cash requirements arising normal course business primarily include debt obligations interest payments see note consolidated financial statements detail companys debt obligations timing expected future principal interest payments tax liabilities connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja additionally company liabilities unrecognized tax benefits including interest penalties see note consolidated financial statements information pertaining transition tax liabilities unrecognized tax benefits operating leases see note consolidated financial statements details companys lease obligations timing expected future lease payments collaborationrelated payments company accrued liabilities contingent salesbased milestone payments related collaborations astrazeneca eisai payment deemed probable company remains subject achievement related salesbased milestone additionally table contents company accrued liabilities future continuation payments related collaboration daiichi sankyo see note consolidated financial statements additional information related future payments purchase obligations purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising purchase obligations also include future inventory purchases company committed connection certain divestitures december company total purchase obligations billion billion estimated payable financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments cost benefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings comprehensive income loss oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded accumulated comprehensive loss aocl reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net company also uses balance sheet risk management program mitigate exposure assets liabilities effects volatility foreign exchange merck principally utilizes forward exchange contracts offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument primarily euro swiss franc japanese yen chinese renminbi forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts table contents help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less six months cash flows contracts reported operating activities consolidated statement cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income continuing operations taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aocl either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal risk december company party four payfloating receivefixed interest rate swap contracts designated fair value hedges portion fixedrate notes detailed table millions number interest rate swaps total swap notional debt instrument par value debt held amount notes due companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models table contents critical accounting estimates companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities business combination primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts rebates returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions fair values intangible assets determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain additional marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent related patent term extension net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion iprd table contents project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business combinations involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date contingent salesbased milestones terms certain collaborative arrangements require company make payments contingent upon achievement salesbased milestones salesbased milestones payable merck collaborative partners accrued capitalized subject cumulative amortization catchup determined probable achieved company based future sales forecasts amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized remaining useful life subject impairment testing revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts us sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition collection accounts receivable expected excess one year sales recorded net time value money discounts material us provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases intermediary wholesaler wholesaler charges company back difference price initially paid wholesaler contract price agreed merck customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected table contents provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued merck remains committed b program providing b discounts eligible covered entities see note consolidated financial statements information regarding b legal proceedings summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside us variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch thecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales outside us returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products longer payment terms including keytruda payment terms days payment terms vaccines sales us typically range days outside us payment terms typically days days although certain markets longer payment terms distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin regulatory approval considered company probable company monitors status respective product research regulatory approval process company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support table contents realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year table contents sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense continuing operations million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weightedaverage period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans primarily attributable lower settlement charges incurred certain plans compared well changes expected returns discount rates company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans compared company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net gainloss amounts primarily reflect differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aocl expected returns pension plans based calculated marketrelated value assets net gainloss amounts aocl table contents excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring program activities result company made estimates judgments regarding future plans including future employee termination costs incurred conjunction involuntary separations separations probable estimable accruing termination costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance employeerelated costs well costs facility shutdown costs reflected within restructuring costs assetrelated charges reflected within cost sales selling general administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires conjunction business combination represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects company evaluates iprd impairment least annually frequently impairment indicators exist unfavorable clinical trial data changes commercial landscape delays clinical development program related regulatory filing approval timelines performing quantitative test compares fair value iprd intangible asset carrying value impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations table contents taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs environmental sustainability initiatives one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive loss income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income continuing operations taxes taxes income continuing operations net income continuing operations less net income attributable noncontrolling interests net income continuing operations attributable merck co inc income discontinued operations net taxes amounts attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders income continuing operations income discontinued operations net income earnings per common share assuming dilution attributable merck co inc common shareholders income continuing operations income discontinued operations net income consolidated statement comprehensive loss income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive loss income net taxes net unrealized loss gain derivatives net reclassifications benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive loss income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased spinoff organon co net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities continuing operations net income continuing operations adjustments reconcile net income continuing operations net cash provided operating activities continuing operations amortization depreciation intangible asset impairment charges income loss investments equity securities net charge acquisition prometheus biosciences inc charge acquisition imago biosciences inc charge acquisition pandion therapeutics inc deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities continuing operations cash flows investing activities continuing operations capital expenditures purchases securities investments proceeds sale seagen inc common stock proceeds sales securities investments acquisition prometheus biosciences inc net cash acquired acquisition imago biosciences inc net cash acquired acquisition acceleron pharma inc net cash acquired acquisition pandion therapeutics inc net cash acquired acquisitions net cash acquired net cash used investing activities continuing operations cash flows financing activities continuing operations net change shortterm borrowings payments debt proceeds issuance debt distribution organon co purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash used provided financing activities continuing operations cash flows discontinued operations net cash provided operating activities net cash used investing activities net cash used financing activities net cash flows provided discontinued operations effect exchange rate changes cash cash equivalents restricted cash net decrease increase cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year includes restricted cash january respectively included current assets cash cash equivalents restricted cash end year includes restricted cash december respectively included current assets accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines including biologic therapies vaccines animal health products companys operations principally managed product basis include two operating segments pharmaceutical animal health reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers farmers pet owners spinoff organon co june merck completed spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise historical results businesses contributed organon spinoff reflected discontinued operations companys consolidated financial statements date spinoff see note summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity method basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired inprocess research development iprd alternative future use charged expense contingent consideration recognized acquisition date table contents foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates results operations translated average exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded comprehensive income oci remain accumulated comprehensive loss aocl either sale complete substantially complete liquidation subsidiary subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost net realizable value cost substantial majority us human health inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered company probable obtaining regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product research regulatory approval process investments investments marketable debt securities classified availableforsale reported fair value fair values companys investments marketable debt securities determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data substantially full term assets liabilities changes fair value impairment related reported net taxes oci company considers available evidence evaluating potential impairments investments marketable debt securities including extent fair value less cost whether allowance credit loss required well adverse factors could affect value securities impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion impairment related factors recognized oci realized gains losses debt securities included income expense net investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net unrealized gains losses investments directly owned determined end reporting period gains losses ownership interests investment funds accounted equity method investments reported one quarter lag investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition table contents accounting guidance certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts us sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition collection accounts receivable expected excess one year sales recorded net time value money discounts material us provision aggregate customer discounts covering chargebacks rebates billion billion billion chargebacks discounts occur contracted customer purchases intermediary wholesaler wholesaler charges company back difference price initially paid wholesaler contract price agreed merck customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside us variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch thecounter products among others outside us returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products longer payment terms including keytruda payment terms days payment terms vaccines sales us typically range days outside us payment terms typically days days although certain markets longer payment terms see note disaggregated revenue disclosures depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion table contents advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development costs included property plant equipment addition company capitalizes certain costs incurred implement cloud computing arrangement considered service agreement included assets capitalized software costs amortized periods ranging years longer lives generally associated enterprisewide projects implemented multiple years costs incurred preliminary project stage post implementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangibles intangibles acquired business combination include product rights trade names patents licenses initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion iprd project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales transaction accounted business combination fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings significant events increase decrease probability achieving development regulatory milestones increase decrease projected cash flows result corresponding increases decreases fair values related contingent consideration obligations research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration associated iprd assets research table contents development expenses also include upfront milestone payments related asset acquisitions licensing transactions involving clinical development programs yet received regulatory approval collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners merck principal sales transactions third parties company recognizes sales cost sales selling general administrative expenses gross basis profit sharing amounts pays collaborative partners recorded within cost sales collaborative partner principal sales transactions third parties company records profit sharing amounts received collaborative partners alliance revenue within sales alliance revenue recorded net cost sales includes adjustment share commercialization costs partners accordance collaboration agreement adjustment determined comparing commercialization costs merck incurred directly reported within selling general administrative expenses costs collaborative partner incurred research development costs merck incurs related collaborations recorded within research development expenses cost reimbursements collaborative partner payments received collaborative partner share costs pursuant terms collaboration agreements recorded increases decreases research development expenses addition terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized cost sales estimated useful life corresponding intangible asset provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued capitalized subject cumulative amortization catchup determined probable achieved company amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized cost sales remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grant date fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements future employee termination costs incurred conjunction involuntary separations accrued separations probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income continuing operations company accounts tax effects tax global intangible lowtaxed income gilti certain foreign subsidiaries income tax provision period tax arises companys policy releasing disproportionate income tax effects aocl utilize itembyitem approach reclassifications certain reclassifications made prior year amounts conform current year presentation table contents use estimates consolidated financial statements prepared conformity accounting principles generally accepted us gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities business combination primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts rebates returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates recently adopted accounting standards october financial accounting standards board fasb issued amended guidance requires acquiring entities recognize measure contract assets liabilities business combination accordance existing revenue recognition guidance company adopted guidance effective january adoption guidance impact companys consolidated financial statements prior acquisitions however impact future periods dependent upon contract assets contract liabilities acquired future business combinations june fasb issued guidance related fair value measurement equity security subject contractual restrictions prohibit sale equity security new guidance also introduces new disclosure requirements equity securities subject contractual sale restrictions measured fair value company adopted guidance effective july impact companys consolidated financial statements upon adoption recently issued accounting standards yet adopted august fasb issued amended guidance requires newly formed joint venture recognize initially measure assets liabilities fair value upon formation amended guidance includes exceptions fair value measurement consistent accounting business combinations guidance amended guidance effective prospectively joint ventures formation date january however existing joint ventures option apply guidance retrospectively early adoption permitted interim annual periods company anticipates impact consolidated financial statements upon adoption november fasb issued guidance intended improve reportable segment disclosure requirements primarily expanded disclosures significant segment expenses guidance effective annual periods beginning interim periods beginning early adoption permitted guidance result incremental disclosures companys segment reporting disclosures december fasb issued guidance intended improve transparency income tax disclosures requiring consistent categories disaggregation information effective income tax rate reconciliation income taxes paid disclosures jurisdiction guidance also includes amendments improve effectiveness income tax disclosures removing certain previously required disclosures guidance effective annual reporting early adoption permitted company currently evaluating impact adoption disclosures within consolidated financial statements acquisitions research collaborations licensing agreements company continues pursue acquisitions establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development also include option continuation payments company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results recent transactions february merck entered definitive agreement acquire aqua business elanco animal health incorporated elanco billion cash elanco aqua business acquired consists table contents innovative portfolio medicines vaccines nutritionals supplements aquatic species two related aqua manufacturing facilities canada vietnam well research facility chile upon closing acquisition broaden merck animal healths aqua portfolio products clynav new generation dnabased vaccine protects atlantic salmon pancreas disease imvixa antiparasitic sea lice treatment acquisition also brings portfolio water treatment products warm water production complementing merck animal healths warm water vaccine portfolio addition products dnabased vaccine technology part business potential accelerate development novel vaccines address unmet needs aqua industry acquisition expected completed mid subject approvals regulatory authorities customary closing conditions transaction accounted acquisition business january merck entered agreement acquire harpoon therapeutics inc harpoon clinicalstage immunotherapy company developing novel class tcell engagers designed harness power bodys immune system treat patients suffering cancer diseases terms agreement merck acquire outstanding shares harpoon per share cash approximate total equity value million harpoons lead candidate hpn tcell engager targeting deltalike ligand dll inhibitory canonical notch ligand expressed high levels smallcell lung cancer neuroendocrine tumors hpn currently evaluated phase clinical trial monotherapy patients advanced cancers associated expression dll also combination atezolizumab patients certain types smallcell lung cancer closing acquisition expected first half subject certain conditions including approval merger harpoons stockholders expiration waiting period hartscottrodino antitrust improvements act customary conditions proposed transaction closes company anticipates accounted acquisition asset since hpn accounts substantially fair value gross assets acquired excluding cash deferred income taxes company expects record charge approximately million research development expenses upon closing transactions october merck daiichi sankyo entered global development commercialization agreement three daiichi sankyos deruxtecan dxd antibody drug conjugate adc candidates patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk see note additional information related collaboration june merck acquired prometheus biosciences inc prometheus clinicalstage biotechnology company pioneering precision medicine approach discovery development commercialization novel therapeutic companion diagnostic products treatment immunemediated diseases total consideration paid billion included billion costs settle sharebased equity awards including million settle unvested equity awards prometheus lead candidate tulisokibart mk formerly pra humanized monoclonal antibody directed tumor necrosis factorlike ligand target associated intestinal inflammation fibrosis tulisokibart developed treatment immunemediated diseases including ulcerative colitis crohns disease autoimmune conditions phase clinical trial evaluating tulisokibart ulcerative colitis commenced transaction accounted acquisition asset since tulisokibart accounted substantially fair value gross assets acquired excluding cash deferred income taxes merck recorded net assets million including cash million investments million deferred tax assets million net liabilities million well charge billion research development expenses related transaction future contingent payments associated acquisition february merck kelunbiotech holding subsidiary sichuan kelun pharmaceutical co ltd closed license collaboration agreement expanding relationship merck gained exclusive rights research development manufacture commercialization seven investigational preclinical adcs treatment cancer kelunbiotech retained right research develop manufacture commercialize certain licensed option adcs chinese mainland hong kong macau merck made upfront payment million recorded research development expenses october merck notified kelunbiotech terminating two seven candidates agreement kelun biotech remains eligible receive future contingent payments aggregating million developmentrelated payments billion regulatory milestones billion salesbased milestones kelunbiotech retain chinese mainland hong kong macau rights option adcs remaining candidates achieve regulatory approval addition kelunbiotech eligible receive tiered royalties ranging midsingledigit rate low doubledigit rate future net sales commercialized adc product also connection agreement merck invested million kelunbiotech shares january table contents january merck acquired imago biosciences inc imago clinicalstage biopharmaceutical company developing new medicines treatment myeloproliferative neoplasms bone marrow diseases billion including payments settle sharebased equity awards also incurred approximately million transaction costs imagos lead candidate bomedemstat mk formerly img investigational orally available lysinespecific demethylase inhibitor currently evaluated multiple clinical trials treatment essential thrombocythemia myelofibrosis polycythemia vera addition indications phase clinical trial evaluating bomedemstat treatment certain patients essential thrombocythemia underway transaction accounted acquisition asset since bomedemstat represented substantially fair value gross assets acquired excluding cash deferred income taxes merck recorded net assets million well charge billion research development expenses related transaction future contingent payments associated acquisition transactions october merck royalty pharma plc royalty pharma entered funding arrangement royalty pharma paid merck million cofund mercks development costs phase b trial mk investigational oral phosphodiesterase pdea inhibitor evaluated treatment schizophrenia royalty pharma sharing risk technical regulatory success merck development funding recognized merck obligation perform contractual services accordingly payment received recognized merck reduction research development expenses ratably estimated phase b research period agreement royalty pharma rights mk decisionmaking authority program merck elects advance mk phase study royalty pharma option provide additional funding development costs million royalty pharma eligible receive royalties future sales royalty pharma elects provide additional funding noted royalty pharma becomes eligible receive future regulatory milestone payments contingent upon certain marketing approvals well higher royalty rate merck record milestone payments expense within income expense net upon receipt related approvals september merck exercised option jointly develop commercialize v mrna investigational individualized neoantigen therapy pursuant terms existing collaboration license agreement moderna inc moderna see note additional information related collaboration august merck orna therapeutics orna biotechnology company pioneering new investigational class engineered circular rna orna therapies entered collaboration agreement discover develop commercialize multiple programs including vaccines therapeutics areas infectious disease oncology terms agreement merck made upfront payment orna million recorded research development expenses addition orna eligible receive future contingent payments aggregating million development related payments million regulatory milestones billion salesbased milestones associated progress multiple vaccine therapeutic programs well royalties ranging highsingledigit rate lowdoubledigit rate approved products derived collaboration merck also invested million ornas series b preferred shares july merck orion corporation orion announced global codevelopment cocommercialization agreement orions investigational candidate odm mk drugs targeting cytochrome p cypa enzyme important steroid production mk oral nonsteroidal inhibitor cypa currently evaluated phase clinical trial treatment patients metastatic castrationresistant prostate cancer merck made upfront payment orion million recorded research development expenses orion responsible manufacture clinical commercial supply mk addition contract provides parties option convert initial codevelopment cocommercialization agreement global exclusive license merck option exercised merck would assume full responsibility past development commercialization expenses associated program since inception agreement well future development commercialization expenses addition orion would eligible receive milestone payments associated progress development commercialization mk well tiered doubledigit royalties sales product approved also july merck kelunbiotech closed license collaboration agreement merck gained exclusive worldwide rights development manufacture commercialization investigational adc mk treatment solid tumors terms agreement merck kelunbiotech collaborate early clinical development investigational adc merck made upfront payment million recorded research development expenses kelunbiotech also eligible receive future contingent milestone payments aggregating million developmental milestones million table contents regulatory milestones million salesbased milestones agreement also provides merck pay tiered royalties ranging midsingle digit rate lowdoubledigit rate future net sales may connection existing arrangement merck exercised option obtain exclusive license outside chinese mainland hong kong macau taiwan development manufacture commercialization kelunbiotechs trophoblast antigen troptargeting adc programs including lead compound skb mk currently phase clinical development terms agreement merck kelunbiotech collaborate certain early clinical development plans including evaluating potential mk monotherapy combination keytruda advanced solid tumors upon option exercise merck made payment million recorded research development expenses additionally merck made additional payment million upon technology transfer merck also agreed make quarterly payments aggregating million fund kelunbiotechs ongoing research development activities million paid december addition kelunbiotech eligible receive future contingent milestone payments include program compounds aggregating million developmental milestones million first commercial sale milestones million salesbased milestones agreement also provides merck pay tiered royalties ranging midsingledigit rate lowdoubledigit rate future net sales transactions november merck acquired acceleron pharma inc acceleron publicly traded biopharmaceutical company total consideration billion accelerons development work focused evaluating transforming growth factor tgfbeta superfamily proteins known play central role regulation cell growth differentiation repair accelerons lead therapeutic candidate sotatercept mk novel mechanism action potential improve shortterm andor longterm clinical outcomes patients pulmonary arterial hypertension pah sotatercept priority review us also review european union eu treatment certain adult patients pah previous agreement assumed merck bristolmyers squibb company bms granted exclusive license develop commercialize sotatercept outside pulmonary hypertension ph field merck would eligible receive contingent milestones royalty payments however merck retains worldwide exclusive rights develop commercialize sotatercept ph field agreement provides merck pay royalties future sales sotatercept ph field bms addition sotatercept accelerons portfolio included reblozyl luspatercept developed commercialized global collaboration bms see note additional information related collaboration transaction accounted business combination company incurred million costs directly related acquisition acceleron consisting primarily sharebased compensation payments settle nonvested equity awards attributable postcombination service severance well investment banking legal fees costs included selling general administrative expenses research development costs estimated fair value assets acquired liabilities assumed acceleron inclusive measurement period adjustments follows november cash cash equivalents investments identifiable intangible assets iprd sotatercept product rights reblozyl year useful life deferred income tax liabilities net assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair value identifiable intangible assets related sotatercept reblozyl determined using income approach specifically multiperiod excess earnings method future probabilityweighted net cash flows discounted present value utilizing discount rate sotatercept reblozyl actual cash flows likely different assumed goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated pharmaceutical segment goodwill deductible tax purposes table contents april merck acquired pandion therapeutics inc pandion clinicalstage biotechnology company developing novel therapeutics designed address unmet needs patients living autoimmune diseases pandions development work focused advancing pipeline precision immune modulators targeting critical immune control nodes total consideration paid billion included million costs primarily comprised sharebased compensation payments settle equity awards transaction accounted acquisition asset merck recorded net assets million primarily cash charge billion research development expenses related transaction future contingent payments associated acquisition march merck gilead sciences inc gilead entered agreement jointly develop commercialize longacting treatments hiv combine mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir gileads investigational capsid inhibitor lenacapavir upfront payment made either party upon entering agreement initial focus collaboration longacting oral formulations longacting injectable formulations combination products formulations potentially added collaboration mutually agreed parties continue study longacting oral formulation combination products terminated studies longacting injectable formulations combination products furthermore merck gilead subsequently amended agreement include joint development commercialization longacting injectable formulation lenacapavir gs development candidate resulting collaboration scripps research gilead novel prodrug islatravir terms agreement merck gilead share operational responsibilities well development commercialization marketing costs future revenues global development commercialization costs shared gilead merck across oral injectable formulation programs longacting oral products gilead lead commercialization us merck lead commercialization eu rest world longacting injectable products merck lead commercialization us gilead lead commercialization eu rest world gilead merck copromote us certain major markets merck gilead share global product revenues equally product revenues surpass certain preagreed per formulation revenue tiers upon passing billion year net product sales oral combination revenue split adjust gilead merck revenues threshold upon passing billion year net product sales injectable combination revenue split adjust gilead merck revenues threshold beyond potential combinations investigational lenacapavir investigational islatravir gilead option license certain mercks investigational oral integrase inhibitors develop combination lenacapavir reciprocally merck option license certain gileads investigational oral integrase inhibitors develop combination islatravir company may exercise option investigational oral integrase inhibitor company following completion first phase clinical trial integrase inhibitor upon exercise option companies split development costs revenues unless nonexercising company decides optout december us food drug administration fda placed full partial clinical holds investigational new drug applications certain oral implant injectable formulations islatravir based observations decreases total lymphocyte cd tcell counts participants receiving islatravir clinical studies phase clinical trial evaluating oral onceweekly combination lower dose islatravir lenacapavir virologically suppressed adults completed enrollment investigational new drug application islatravir lenacapavir onceweekly treatment regimen remains partial clinical hold studies would use islatravir doses higher doses considered revised clinical program company remains committed developing compounds longacting hiv prevention believes potential nucleoside reverse transcriptase translocation inhibitor nrtti mechanism collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed table contents astrazeneca plc merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda imfinzi companies also jointly developing commercializing astrazenecas koselugo selumetinib multiple indications terms agreement astrazeneca merck share development commercialization costs lynparza koselugo monotherapy nonpdlpd combination therapy opportunities profits lynparza koselugo product sales generated monotherapies combination therapies shared equally astrazeneca principal lynparza koselugo sales transactions merck records share lynparza koselugo product sales net cost sales commercialization costs alliance revenue share development costs associated collaboration part research development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca also made payments multiyear period certain license options addition agreement provides contingent payments merck astrazeneca related successful achievement salesbased regulatory milestones merck made salesbased milestone payment astrazeneca million previously accrued additionally merck determined probable sales lynparza future would trigger million salesbased milestone payment merck astrazeneca accordingly merck recorded million liability remained accrued december corresponding increase intangible asset related lynparza merck also recognized million cumulative amortization catchup expense related recognition milestone potential future salesbased milestone payments billion yet accrued deemed company probable time lynparza received regulatory approvals triggering capitalized milestone payments million million respectively merck astrazeneca january merck made additional million regulatory milestone payment astrazeneca potential future regulatory milestone payments million remain agreement intangible asset balance related lynparza includes capitalized salesbased regulatory milestone payments billion december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sales selling general administrative research development december receivables astrazeneca included current assets payables astrazeneca included accrued current liabilities payables astrazeneca included noncurrent liabilities represents amortization capitalized milestone payments amount includes million cumulative amortization catchup expense noted includes accrued milestone payments eisai co ltd merck eisai co ltd eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor table contents discovered eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai records lenvima product sales globally eisai principal lenvima sales transactions merck eisai share applicable profits equally merck records share lenvima product sales net cost sales commercialization costs alliance revenue expenses incurred co development shared two companies accordance collaboration agreement reflected research development expenses certain expenses incurred solely merck eisai shareable collaboration agreement including costs incurred excess agreed upon caps costs related certain combination studies keytruda lenvima agreement merck made upfront payment eisai also made payments multiyear period certain option rights addition agreement provides contingent payments merck eisai related successful achievement salesbased regulatory milestones merck made salesbased milestone payments eisai aggregating million million million respectively merck determined probable sales lenvima future would trigger million salesbased milestone payments merck eisai accordingly merck recorded million liabilities million subsequently paid noted million remained accrued december corresponding increases intangible asset related lenvima merck also recognized million cumulative amortization catchup expense related recognition milestones potential future salesbased milestone payments billion yet accrued deemed company probable time lenvima received regulatory approvals triggering capitalized milestone payments million million respectively merck eisai regulatory milestone payments remaining agreement intangible asset balance related lenvima includes capitalized salesbased regulatory milestone payments million december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue lenvima cost sales selling general administrative research development december receivables eisai included current assets payables eisai included accrued current liabilities represents amortization capitalized milestone payments amount includes million cumulative amortization catchup expense noted represents accrued milestone payment bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas riociguat two companies implemented joint development commercialization strategy collaboration also includes development bayers verquvo vericiguat approved us eu japan since approved several markets agreement bayer commercializes adempas americas merck commercializes rest world verquvo merck commercializes us bayer commercializes rest world companies share development costs profits sales merck records sales adempas verquvo marketing territories well alliance revenue alliance revenue represents mercks share profits sales adempas verquvo bayers marketing territories product sales net cost sales commercialization costs cost sales includes bayers share profits sales mercks marketing territories table contents addition agreement provided contingent payments merck bayer related successful achievement salesbased milestones merck made final million salesbased milestone payment collaboration bayer intangible asset balances related adempas includes acquired intangible asset balance well capitalized salesbased milestone payments attributed adempas verquvo reflects portion final salesbased milestone payment attributed verquvo million million respectively december included intangibles net assets amortized estimated useful lives adempas verquvo supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue adempasverquvo net sales adempas recorded merck net sales verquvo recorded merck total sales cost sales selling general administrative research development december receivables bayer included current assets payables bayer included accrued current liabilities includes amortization intangible assets amount includes million cumulative amortization catchup expense ridgeback biotherapeutics lp merck ridgeback biotherapeutics lp ridgeback closely held biotechnology company entered collaboration agreement develop lagevrio molnupiravir investigational orally available antiviral candidate treatment patients covid merck gained exclusive worldwide rights develop commercialize lagevrio related molecules following initial authorizations certain markets fourth quarter lagevrio since received multiple additional authorizations terms agreement ridgeback received upfront payment eligible receive future contingent payments dependent upon achievement certain developmental regulatory approval milestones agreement also provides merck reimburse ridgeback portion certain thirdparty contingent milestone payments royalties net sales part profitsharing calculation merck principal sales transactions recognizing sales related costs profitsharing amounts recorded within cost sales profits collaboration split equally partners reimbursements ridgeback share research development costs deducted ridgebacks share profits reflected decreases research development expenses summarized financial information related collaboration follows years ended december net sales lagevrio recorded merck cost sales selling general administrative research development december payables ridgeback included accrued current liabilities includes royalty expense amortization capitalized milestone payments inventory reserves includes accrued royalties amount december also includes accrued milestone payment table contents bristolmyers squibb company reblozyl luspaterceptaamt firstinclass erythroid maturation recombinant fusion protein obtained part mercks november acquisition acceleron commercialized global collaboration bms reblozyl approved us europe certain markets treatment anemia certain rare blood disorders also evaluated additional indications hematology therapies bms principal sales transactions reblozyl however merck copromotes reblozyl copromote future products approved collaboration north america reimbursed bms merck receives sales royalty bms could increase maximum based sales levels royalty reduced upon earlier patent expiry generic entry indicationbyindication basis market additionally merck eligible receive future contingent salesbased milestone payments million alliance revenue related collaboration recorded within sales consists royalties also includes receipt regulatory approval milestone payment million merck recorded alliance revenue related collaboration million million million moderna inc september merck exercised option jointly develop commercialize v mrna investigational individualized neoantigen therapy pursuant terms existing collaboration license agreement moderna resulted million payment charged research development expenses v mrna currently evaluated combination keytruda multiple phase clinical trials merck moderna share costs profits equally worldwide collaboration merck records share development costs associated collaboration part research development expenses reimbursements received moderna research development expenses recognized reductions research development costs summarized financial information related collaboration follows years ended december selling general administrative research development december payables moderna included accrued current liabilities expenses include million option payment noted daiichi sankyo october merck daiichi sankyo entered global development commercialization agreement three daiichi sankyos dxd adc candidates patritumab deruxtecan herdxd mk ifinatamab deruxtecan idxd mk raludotatug deruxtecan rdxd mk three potentially firstinclass dxd adcs various stages clinical development treatment multiple solid tumors monotherapy andor combination treatments companies jointly develop potentially commercialize adc candidates worldwide except japan daiichi sankyo maintain exclusive rights daiichi sankyo solely responsible manufacturing supply terms agreement merck made payments daiichi sankyo totaling billion payments included billion million patritumab deruxtecan ifinatamab deruxtecan may refundable prorated basis event early termination development respect either program addition agreement provides continuation payment million related patritumab deruxtecan due merck october continuation payment million related raludotatug deruxtecan due merck october merck make continuation payments dates noted either patritumab deruxtecan raludotatug deruxtecan rights applicable program revert daiichi sankyo nonrefundable upfront payments already paid retained daiichi sankyo agreement also provides contingent payments merck daiichi sankyo additional billion dxd adc upon successful achievement certain salesbased milestones following regulatory approval daiichi sankyo generally record sales worldwide daiichi sankyo principal sales transactions companies equally share expenses well profits worldwide except japan daiichi sankyo retains exclusive rights merck receive salesbased royalty merck record share product sales net cost sales commercialization costs alliance revenue raludotatug deruxtecan merck responsible first billion research development expenses excess allowable research development expenses companies share equally table contents expenses well profits worldwide merck include share development costs associated collaboration part research development expenses conjunction transaction merck recorded aggregate pretax charge billion research development expenses billion upfront payments billion continuation payments merck determined appropriate expense billion refundable portion consideration significant number clinical studies currently underway planned near future well certain studies advanced stages makes highly likely programs continue progress incur substantial expenses therefore likelihood programs terminating end refundable period remote merck also determined appropriate expense continuation payments upon execution agreement payments result company gaining additional intellectual property rights addition significant number ongoing planned clinical studies shortterm nature option period makes likelihood merck making payments remote spinoff organon co june merck completed spinoff organon distribution organons publicly traded stock company shareholders connection spinoff merck shareholder received onetenth share organons common stock share merck common stock held shareholder distribution treated tax free merck shareholders us federal income tax purposes indebtedness billion principal amount consisting term loans senior notes issued connection spinoff assumed organon merck longer obligor organon debt financing arrangements cash proceeds billion distributed organon merck connection spinoff also connection spinoff merck organon entered separation distribution agreement also entered various agreements effect spinoff provide framework relationship merck organon spinoff including transition services agreement tsa manufacturing supply agreements msas trademark license agreements intellectual property license agreements employee matters agreement tax matters agreement certain commercial agreements tsa merck providing organon various services similarly organon providing merck various services majority services provided tsa terminated within months following spinoff majority remaining services terminate within months following spinoff merck organon also entered series interim operating agreements pursuant various jurisdictions merck held licenses permits rights connection marketing import andor distribution organon products prior separation merck continued market import distribute products time relevant licenses permits transferred organon interim operating agreements accordance separation distribution agreement merck continued operations affected markets behalf organon organon receiving economic benefits burdens activities december one jurisdiction remains interim operating agreement additionally merck organon entered number msas pursuant merck manufacturing supplying certain active pharmaceutical ingredients organon b manufacturing supplying certain formulated pharmaceutical products organon c packaging labeling certain finished pharmaceutical products organon similarly organon merck entered number msas pursuant organon manufacturing supplying certain formulated pharmaceutical products merck b packaging labeling certain finished pharmaceutical products merck terms msas range initial duration four years ten years amounts included consolidated statement income msas include sales million million million respectively related cost sales million million million respectively amounts included consolidated statement income tsas immaterial amounts due organon agreements million million december respectively reflected current assets amounts due organon agreements million million december respectively included accrued current liabilities results womens health biosimilars established brands businesses previously included pharmaceutical segment contributed organon spinoff well interest expense related debt issuance reflected discontinued operations companys consolidated statement income income discontinued operations net taxes amounts attributable noncontrolling interests periods prior spinoff june merck incurred separation costs million related spinoff organon also included income discontinued operations net taxes table contents amounts attributable noncontrolling interests costs primarily relate professional fees separation activities within finance tax legal information technology functions well investment banking fees details income discontinued operations net taxes amounts attributable noncontrolling interests follows year ended december sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income discontinued operations taxes tax provision income discontinued operations net taxes less income discontinued operations attributable noncontrolling interests reflects amounts june spinoff date restructuring restructuring program january company approved new restructuring program restructuring program intended continue optimization companys human health global manufacturing network future pipeline shifts new modalities also optimize animal health global manufacturing network improve supply reliability increase efficiency actions contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested remainder costs result cash outlays relating primarily facility shutdown costs company recorded total pretax costs million related restructuring program restructuring program merck approved global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint company recorded total pretax costs million million million related restructuring program since inception restructuring program december merck recorded total pretax accumulated costs approximately billion approximately cumulative pretax costs cash outlays primarily related employee separation expense facility shutdown costs approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested actions restructuring program substantially complete segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring programs type cost separation accelerated costs depreciation exit costs total year ended december restructuring program cost sales restructuring costs restructuring program cost sales selling general administrative research development restructuring costs year ended december restructuring program cost sales selling general administrative research development restructuring costs year ended december restructuring program cost sales selling general administrative research development restructuring costs separation costs associated actual headcount reductions well involuntary headcount reductions probable could reasonably estimated accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors exit costs include asset abandonment facility shutdown related costs well pretax gains losses resulting sales facilities related assets additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note sharebased compensation table contents following table summarizes charges spending relating restructuring program activities program separation accelerated costs depreciation exit costs total restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments cost benefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded aocl reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes table contents company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net company also uses balance sheet risk management program mitigate exposure assets liabilities effects volatility foreign exchange merck principally utilizes forward exchange contracts offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument primarily euro swiss franc japanese yen chinese renminbi forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less six months cash flows contracts reported operating activities consolidated statement cash flows company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aocl either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci effects companys net investment hedges oci consolidated statement income shown amount pretax gain loss recognized amount pretax gain loss recognized income expense net amounts excluded comprehensive income effectiveness testing years ended december net investment hedging relationships foreign exchange contracts eurodenominated notes amounts reclassified aocl income related sale subsidiary interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal risk december company party four payfloating receivefixed interest rate swap contracts designated fair value hedges portion fixedrate notes detailed table number interest rate swaps total swap notional par value debt held amount notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark secured overnight financing rate sofr swap rate fair value changes notes attributable changes sofr swap rate recorded interest expense along offsetting fair table contents value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows table presents location amounts recorded consolidated balance sheet related cumulative basis adjustments fair value hedges december cumulative amount fair value hedging adjustment increase decrease included carrying amount hedged liabilities carrying amount balance sheet caption longterm debt presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar asset liability notional asset liability notional derivatives designated hedging instruments balance sheet caption interest rate swap contracts noncurrent assets foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments balance sheet caption foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amounts subject offset master netting arrangements offset consolidated balance sheet cash collateral receivedposted net amounts table contents table provides information regarding location amount pretax gains losses derivatives designated fair value cash flow hedging relationships years ended december financial statement caption effects fair value cash flow hedges recorded sales income expense net comprehensive income loss loss gain fair value hedging relationships interest rate swap contracts hedged items derivatives designated hedging instruments impact cash flow hedging relationships foreign exchange contracts amount gain recognized oci derivatives increase decrease sales result aocl reclassifications interest rate contracts amount gain recognized income expense net derivatives amount gain loss recognized oci derivatives interest expense component income expense net table provides information regarding income statement effects derivatives designated hedging instruments amount derivative pretax gain loss recognized income years ended december derivatives designated hedging instruments income statement caption foreign exchange contracts income expense net foreign exchange contracts sales derivative contracts primarily mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates amount includes loss forward exchange contracts entered conjunction spinoff organon derivative contracts serve economic hedges forecasted transactions december company estimates million pretax net unrealized losses derivatives maturing within next months hedge foreign currency denominated sales period reclassified aocl sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized amortized fair amortized fair cost gains losses value cost gains losses value commercial paper us government agency securities corporate notes bonds total debt securities publicly traded equity securities total debt publicly traded equity securities unrealized net gains million recorded income expense net equity securities still held december unrealized net losses million recorded income expense net equity securities still held december december company also million equity investments without readily determinable fair values included assets company records unrealized gains equity investments based favorable observable price changes transactions involving similar investments investee records unrealized losses based unfavorable observable price changes included income expense net company recorded unrealized gains million unrealized losses million related certain equity investments still held december company recorded unrealized gains million unrealized losses million related certain equity investments still held december cumulative unrealized gains cumulative unrealized losses based observable price changes investments equity investments without readily determinable fair values still held december million million respectively december company also million million billion respectively recorded assets equity securities held ownership interests investment funds losses gains recorded income expense net relating investment funds million billion billion years ended december respectively fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using level level level total level level level total assets investments commercial paper publicly traded equity securities assets us government agency securities corporate notes bonds publicly traded equity securities derivative assets forward exchange contracts purchased currency options interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts written currency options total liabilities investments included assets restricted use including payment benefits employee benefit plans balance december includes securities total fair value million subject contractual sale restriction expires july fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant december cash cash equivalents included billion billion cash equivalents respectively would considered level fair value hierarchy contingent consideration summarized information changes fair value liabilities contingent consideration associated business combinations follows fair value january changes estimated fair value payments fair value december recorded cost sales research development expenses income expense net includes cumulative translation adjustments december million million respectively liabilities relate termination sanofi pasteur msd joint venture part termination merck recorded liability contingent future royalty payments net sales merck products previously sold joint venture december fair value liability determined utilizing estimated amount timing projected cash flows using riskadjusted discount rate present value cash flows balance december includes million recorded current liability amounts expected paid within next months table contents payments contingent consideration years relate sanofi pasteur msd liabilities described fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales us europe china primarily due drug wholesalers distributors retailers hospitals government agencies company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business companys customers largest accounts receivable balances mckesson corporation cencora inc cardinal health inc represented approximately respectively total accounts receivable december accounts receivable balance december chongqing zhifei biological products co ltd zhifei sole distributor companys vaccines products china significant china part companys factoring program discussed however vaccine sales distributed zhifei represent substantial portion total sales china company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable company factored billion billion accounts receivable december respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions generally within thirty days receipt december company collected million million respectively behalf financial institutions reflected restricted cash current assets related obligation remit cash within accrued current liabilities net cash flows related collections reported financing activities consolidated statement cash flows cost factoring accounts receivable de minimis derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty cash collateral received company various counterparties million million december respectively obligation return collateral recorded accrued current liabilities cash collateral advanced company various counterparties million december table contents inventories inventories december consisted finished goods raw materials work process supplies decrease lifo cost recognized inventories assets inventories valued lifo method comprised approximately billion december reflecting decrease lifo cost amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical animal health total balance january balance december balance december includes cumulative translation adjustments goodwill balances accumulated goodwill impairment losses million december acquired intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net product rights iprd trade names licenses significant acquired intangibles included product rights net basis related human health marketed products december reblozyl billion zerbaxa million sivextro million additionally company billion net acquired intangibles related animal health december billion related product rights billion attributable trade names primarily related allflex december iprd primarily relates mk sotatercept billion obtained acquisition acceleron see note mk nemtabrutinib million obtained acquisition arqule inc arqule see significant net intangible assets included licenses december include lynparza billion related collaboration astrazeneca lenvima million related collaboration eisai adempas million related collaboration bayer see note additional information related intangible assets associated collaborations table contents iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion iprd project company make separate determination thenuseful life asset begin amortization company recorded million iprd impairment charge within research development expenses related mk gefapixant nonnarcotic oral selective px receptor antagonist development treatment refractory chronic cough unexplained chronic cough adults december fda issued complete response letter crl regarding resubmission mercks new drug application nda gefapixant crl fda concluded mercks application meet substantial evidence effectiveness treating refractory chronic cough unexplained chronic cough crl related safety gefapixant marketing application gefapixant based results cough cough clinical trials january fda issued crl regarding mercks original nda gefapixant crl fda requested additional information related cough counting system used assess efficacy receipt second crl fda constituted triggering event required evaluation gefapixant intangible asset impairment company estimated current fair value gefapixant utilizing income approach calculates present value projected future cash flows market participant assumptions used derive forecasted cash flows updated reflect revised market launch plans resulting reduction estimated fair value revised estimated fair value gefapixant compared related carrying value resulted impairment charge noted remaining intangible asset balance related lyfnua gefapixant million included product rights table december amortized expected useful life supported projected future cash flows markets approved including japan eu company recorded billion intangible asset impairment charges within research development expenses billion represents iprd impairment charges related nemtabrutinib mk oral reversible noncovalent brutons tyrosine kinase btk inhibitor currently evaluated treatment hematological malignancies obtained acquisition arqule following discussions regulatory authorities third quarter development period nemtabrutinib extended constituted triggering event required evaluation nemtabrutinib intangible asset impairment company estimated current fair value nemtabrutinib utilizing income approach calculates present value projected future cash flows market participant assumptions used derive forecasted cash flows updated reflect delay anticipated launch date nemtabrutinib resulted lower cumulative revenue forecasts reduction estimated fair value revised estimated fair value nemtabrutinib compared related carrying value resulted million impairment charge recorded third quarter december regulatory authorities provided additional feedback respect clinical study design led reassessment development plan nemtabrutinib expected result changes clinical study design corresponding delays anticipated approval launch timelines constituted triggering event utilizing income approach forecasted cash flows updated reflect decline forecasted revenue coupled increase development cost forecasts reduced projected cash flows lowering estimated current fair value nemtabrutinib revised estimated fair value nemtabrutinib compared thenrelated carrying value resulted million impairment charge remaining iprd intangible asset related nemtabrutinib million assumptions used estimate fair value nemtabrutinib prove incorrect development nemtabrutinib progress anticipated thereby adversely affecting projected future cash flows company may record additional impairment charge future charge could material company also recorded million intangible asset impairment charge related derazantinib resulting termination outlicensing agreement decision merck pursue development derazantinib company recorded million iprd impairment charge within research development expenses related nemtabrutinib part mercks annual impairment assessment iprd intangible assets company estimated current fair value nemtabrutinib utilizing projected future cash flows market participant assumptions used derive forecasted cash flows updated reflect current competitive landscape nemtabrutinib including increased expected development costs additional clinical trial data needed develop nemtabrutinib well delay anticipated launch date nemtabrutinib collectively reduced projected future cash flows estimated fair value additionally discount rate utilized determine current fair value asset reduced reflect current risk profile asset revised estimated fair value nemtabrutinib compared related carrying value resulted iprd impairment charge noted table contents iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within cost sales billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion loans payable longterm debt leases loans payable loans payable december included billion notes due million longdated notes subject repayment option holders loans payable december included billion notes due million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively longterm debt longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due notes due debentures due notes due debentures due debentures due notes due eurodenominated notes due presented table includes borrowings variable rates resulted effective interest rates respectively table contents exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date may company issued billion principal amount senior unsecured notes consisting million notes due million notes due billion notes due million notes due billion notes due billion notes due company used portion billion net proceeds offering fund portion cash consideration paid acquisition prometheus see note including related fees expenses used remaining net proceeds general corporate purposes including repay commercial paper borrowings indebtedness upcoming maturities certain companys borrowings require merck comply covenants december company compliance covenants aggregate maturities longterm debt next five years follows billion billion billion billion billion interest payments related debt obligations follows billion billion billion billion billion company billion credit facility matures may facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility leases company operating leases primarily manufacturing facilities research development facilities corporate offices employee housing vehicles certain equipment company determines arrangement lease inception evaluating contracts embedded leases company exercises judgment determine explicit implicit identified asset contract merck controls use asset embedded leases primarily associated contract manufacturing organizations immaterial lease term includes options extend terminate lease reasonably certain merck exercise option real estate leases facilities average remaining lease term approximately seven years include options extend leases five years applicable vehicle leases generally effect four years company elected exclude shortterm leases leases initial term months less lease assets liabilities balance sheet lease expense operating lease payments recognized straightline basis term lease operating lease assets liabilities recognized based present value lease payments lease term since companys leases readily determinable implicit discount rate company uses incremental borrowing rate calculate present value lease payments asset class quarterly basis updated incremental borrowing rate determined based average remaining lease term asset class companys pretax cost debt term updated rates asset class applied prospectively new leases company separate lease components eg payments rent real estate taxes insurance costs nonlease components eg commonarea maintenance costs event agreement contains merck includes lease nonlease components purposes calculating rightofuse asset related lease liability nonlease components fixed vehicle leases employee housing company applies portfolio approach account operating lease assets liabilities certain companys lease agreements contain variable lease payments adjusted periodically inflation actual operating expense trueups compared estimated amounts however amounts immaterial sublease income activity related sale leaseback transactions immaterial mercks lease agreements contain material residual value guarantees material restrictive covenants operating lease cost million million million cash paid amounts included measurement operating lease liabilities million million million operating lease assets obtained exchange lease obligations million million million table contents supplemental balance sheet information related operating leases follows december assets assets liabilities accrued current liabilities noncurrent liabilities weightedaverage remaining lease term years weightedaverage discount rate includes prepaid leases related lease liability maturities operating leases liabilities follows thereafter total lease payments less imputed interest december company entered additional real estate operating leases yet commenced obligations associated leases total million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial condition results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities table contents product liability litigation gardasilgardasil previously disclosed merck defendant product liability lawsuits us involving gardasil human papillomavirus quadrivalent types vaccine recombinant gardasil human papillomavirus valent vaccine recombinant december approximately cases filed pending merck either federal state court actions plaintiffs allege among things suffered various personal injuries vaccination gardasil gardasil postural orthostatic tachycardia syndrome predominate alleged injury august judicial panel multidistrict litigation ordered gardasilgardasil product liability cases pending federal courts nationwide transferred judge robert j conrad western district north carolina coordinated pretrial proceedings fewer product liability cases pending outside us governmental proceedings inflation reduction act previously disclosed june merck filed complaint us district court district columbia us government regarding inflation reduction acts drug price negotiation program medicare program litigation seeks relief program challenging constitutionality violative first fifth amendments us constitution matters previously disclosed april merck received set investigative interrogatories california attorney generals office pursuant investigation conduct agreements allegedly affected delayed competition lantus insulin market interrogatories seek information concerning mercks development insulin glargine product subsequent termination well mercks patent litigation sanofi sa concerning lantus resolution litigation merck cooperating california attorney generals investigation previously disclosed june merck received civil investigative demand cid us department justice cid requests answers interrogatories well various documents regarding temperature excursions thirdparty storage facility containing certain merck products merck cooperating governments investigation intends produce information andor documents necessary response cid previously disclosed time time companys subsidiaries china receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside us authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required commercial litigation zetia antitrust litigation previously disclosed merck msd schering corporation scheringplough corporation msp singapore company llc collectively merck defendants defendants number lawsuits filed behalf direct indirect purchasers zetia ezetimibe alleging violations federal state antitrust laws well state statutory common law causes action cases consolidated federal multidistrict litigation zetia mdl judge rebecca beach smith eastern district virginia previously disclosed april merck defendants reached settlements direct purchaser retailer plaintiffs proposed settlement subject court approval indirect purchaser class agreements merck agreed pay million resolve direct purchaser retailer indirect purchaser plaintiffs claims recorded expense companys financial results october court granted final approval indirect purchaser class settlement table contents united healthcare services inc united healthcare humana inc humana centene corporation others centene kaiser foundation health plan inc kaiser collectively insurer plaintiffs filed lawsuit jurisdiction outside eastern district virginia merck defendants others making similar allegations made zetia mdl well additional allegations vytorin cases transferred eastern district virginia proceed zetia mdl february insurer plaintiffs filed amended complaints march merck defendants jointly defendants moved dismiss certain aspects insurer plaintiffs complaints including claims vytorin damages december prior decision motion dismiss us judicial panel multidistrict litigation remanded four insurer plaintiff cases transferor courts northern district california kaiser district minnesota united healthcare district new jersey humana centene rotateq antitrust litigation previously disclosed march mayor city council baltimore filed putative class action msd eastern district pennsylvania behalf thirdparty payors states indirectly purchased paid andor provided reimbursement purchase price rotateq rotavirus vaccine live oral pentavalent resale march present plaintiff alleges msd violated federal state antitrust laws state consumer protection laws plaintiff alleges msd implemented anticompetitive vaccine bundling scheme whereby msd leverages alleged monopoly power certain pediatric vaccine markets maintain alleged monopoly power us market rotavirus vaccines order charge supracompetitive prices rotateq plaintiff seeks permanent injunctive relief unspecified monetary damages purchases rotateq trebled fees costs may msd moved dismiss complaint november court granted part denied part motion dismiss dismissing plaintiffs idaho utah consumer law claims allowing claims proceed bravecto litigation previously disclosed january company served complaint us district court district new jersey following motion practice plaintiffs filed second amended complaint july seeking certify nationwide class action purchasers users bravecto fluralaner products us territories may july plaintiffs contend bravecto causes neurological events dogs cats alleges violations new jersey consumer fraud act breach warranty product liability related theories company moved dismiss alternatively strike class allegations second amended complaint motion pending similar case filed quebec canada may superior court certified class dog owners quebec gave bravecto chew dogs february november whose dogs experienced one conditions postmarketing adverse reactions section labeling approved november company plaintiffs appealed class certification decision court appeal quebec heard appeal february issued decision april allowing parties appeals part court appeal amended class period start july allowed second plaintiff serve class representative modified list conditions class definition company sought leave appeal supreme court canada denied case proceeding superior court b program litigation previously disclosed merck filed complaint us district court district columbia challenge letter merck received health resources services administration hrsa may regarding mercks b program integrity initiative hrsas letter merck asserts merck violation b statute hrsa claims continued failure provide b price covered entities using contract pharmacies may result civil monetary penalties instance alleged overcharging addition repayment instance overcharging letter similar letters hrsa sent manufacturers letters held unlawful multiple federal courts merck disagrees hrsas assertion merck remains committed b program providing b discounts eligible covered entities mercks b program integrity initiative consistent requirements b statute intended ensure integrity sustainability b statute reducing prohibited duplicate discounts diversion putting patients back center program merck continues offer companys covered outpatient drugs b covered entities purchase b ceiling price september court stayed case pending dc circuits ruling novartis pharmaceuticals corp v johnson united therapeutics corp v johnson table contents qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss pending antitrust suit result false claims act suit antitrust suits proceeded discovery complete parties filed briefed crossmotions summary judgment july false claims act case court denied relators motion summary judgment granted two companys motions summary judgment denied companys remaining motions summary judgment moot court entered judgment favor company dismissed relators amended complaint full prejudice relators appealed decision antitrust case court granted companys motion summary judgment plaintiffs state law claims denied motion plaintiffs antitrust claim november third circuit granted companys petition permission appeal antitrust decision merck kgaa litigation previously disclosed january protect longestablished brand rights us company filed lawsuit merck kgaa darmstadt germany kgaa historically operating emd group us alleging improperly uses name merck us kgaa filed suit company number jurisdictions outside us alleging among things unfair competition trademark infringement andor corporate name infringement certain jurisdictions kgaa also alleges breach parties coexistence agreement litigation ongoing us trial date set also ongoing jurisdictions outside us patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions accounted business combinations potentially significant intangible asset impairment charges bridion previously disclosed january november company received multiple paragraph iv certification letters hatchwaxman act notifying company generic drug companies filed applications fda seeking prepatent expiry approval sell generic versions bridion sugammadex injection march april december company filed patent infringement lawsuits us district courts district new jersey northern district west virginia generic companies actions district new jersey consolidated west virginia case jointly dismissed prejudice august favor proceeding new jersey remaining defendants new jersey action stipulated infringement asserted claims withdrew remaining claims defenses defense seeking shorten patent term extension pte sugammadex patent december us district court district new jersey held oneday trial december remaining pte calculation defense court ordered posttrial briefing defense held closing arguments february new jersey action pending company settled five generic companies providing generic companies bring generic versions bridion market january may delayed applicable pediatric exclusivity earlier certain circumstances company agreed stay lawsuit filed two generic companies exchange agreed bound judgment merits consolidated action district new jersey one generic companies consolidated action table contents requested dismissal action company oppose request subsequently granted court company expect company bring generic version bridion market january later depending applicable pediatric exclusivity previously disclosed june us district court district new jersey ruled mercks favor court held mercks calculation pte sugammadex patent covering compound invalid us patent trademark office correctly granted full fiveyear extension ruling affirms validates mercks us patent protection bridion least january june us district court district new jersey issued final judgment prohibiting fda approving pending tentatively approved generic applications january except subsequent agreements defendants merck order court july defendants filed notice appeal united states court appeals federal circuit appeal currently pending february company received another paragraph iv certification letter hatchwaxman act notifying company hikma pharmaceuticals usa inc filed application fda seeking prepatent expiry approval sell generic version bridion injection company currently considering options januvia janumet janumet xr previously disclosed fda granted pediatric exclusivity respect januvia sitagliptin janumet sitagliptinmetformin hcl janumet xr sitagliptin metformin hcl extendedrelease provides six months exclusivity us beyond expiration patents listed fdas orange book adding exclusivity term key patent protection extended exclusivity products january however januvia janumet janumet xr contain sitagliptin phosphate monohydrate company another patent covering certain phosphate salt polymorphic forms sitagliptin expires may including pediatric exclusivity saltpolymorph patent previously disclosed beginning number generic drug companies filed andas seeking approval generic forms januvia janumet along paragraph iv certifications challenging validity saltpolymorph patent company responded filing infringement suits settled company settled total generic companies providing generic companies bring generic versions januvia janumet market us may earlier certain circumstances generic versions janumet xr market july earlier certain circumstances march company filed patent infringement lawsuit us district court district delaware zydus worldwide dmcc zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus lawsuit company alleged infringement saltpolymorph patent based filing zyduss nda seeking approval form sitagliptin different used januvia december parties reached settlement included dismissal case without prejudice enabling zydus seek final approval nonautomatically substitutable product january company received paragraph iv certification letter hatchwaxman act notifying company zydus filed anda seeking approval sitagliptinmetformin hcl tablets certifying valid enforceable claim patents listed fdas orange book janumet infringed proposed zydus product march parties reached settlement enabling zydus seek final approval non automatically substitutable product containing different form sitagliptin used janumet november company received paragraph iv certification letter hatchwaxman act notifying company zydus filed anda seeking approval sitagliptinmetformin hcl extended release tablets january parties reached settlement enabling zydus seek final approval nonautomatically substitutable version containing different form sitagliptin used janumet xr result settlement agreements related later expiring saltpolymorph patent directed specific sitagliptin salt form products company expects januvia janumet lose market exclusivity us may janumet xr lose market exclusivity us july although zydus received fda approval nonautomatically substitutable form sitagliptin differs form companys sitagliptin products supplementary protection certificates spcs janumet expired april majority european countries prior expiration generic companies sought revocation janumet spcs number european countries february finnish court referred certain questions court justice european union cjeu could determine validity janumet spcs europe oral hearing held march advocate general opinion expected april decision later table contents cjeu renders decision negatively impacts validity janumet spcs throughout europe generic companies prevented launching products spc period certain european countries may action damages countries include belgium czech republic ireland finland france slovakia switzerland janumet spcs ultimately upheld company reserved rights related pursuit damages countries generic launched prior expiry janumet spc october company filed patent infringement lawsuit sawai pharmaceuticals co ltd medisa shinyaku co ltd collectively defendants tokyo district court seeking injunction stop manufacture sale offer sale defendants sitagliptin dihydrogen phosphate product companys patents patent term extensions force lawsuit response defendants application marketing authorization sell generic sitagliptin dihydrogen phosphate product anhydrate form approved august merck asserts defendants activity infringes patent term extension associated mercks patent directed sitagliptin compound patent keytruda previously disclosed company filed complaint johns hopkins university jhu november us district court maryland action concerns patents emerging joint research collaboration merck jhu regarding use pembrolizumab merck sells trade name keytruda merck jhu partnered design conduct clinical study administering keytruda cancer patients tumors genetic biomarker known microsatellite instabilityhigh msih conclusion study jhu secured us patents citing joint research study merck alleges jhu breached collaboration agreement filing obtaining patents without informing involving merck licensing patents others merck therefore brought action breach contract declaratory judgment noninfringement promissory estoppel jhu answered complaint april may denying mercks claims counterclaiming willful infringement nine issued us patents including demand damages november company filed inter partes review united states patent trademark office patent trial appeal board challenging validity patent claims one asserted patents case lynparza december astrazeneca pharmaceuticals lp received paragraph iv certification letter hatchwaxman act notifying astrazeneca natco pharma limited natco filed application fda seeking prepatent expiry approval sell generic versions lynparza olaparib tablet february astrazeneca company filed patent infringement lawsuit us district court district new jerseydelaware natco lawsuit asserts one patents covering olaparib automatically stays fda approval generic application june adverse court decision whichever may occur earlier december astrazeneca pharmaceuticals lp received second paragraph iv certification letter hatchwaxman act notifying astrazeneca sandoz inc filed application fda seeking prepatent expiry approval sell generic versions lynparza olaparib tablet february astrazeneca company filed patent infringement lawsuit us district court district new jersey sandoz lawsuit asserts one patents covering olaparib automatically stays fda approval generic application june adverse court decision whichever may occur earlier litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial condition results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine table contents increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial condition results operations liquidity company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock table contents awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years rsu awards generally vest onethird year threeyear period total pretax sharebased compensation cost recorded million million million respectively amount includes million related continuing operations income tax benefits sharebased compensation expense recognized million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments risk free interest rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december vested expected vest december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options table contents summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december expected vest december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees us certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans including certain costs reported part discontinued operations consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service credit cost net loss gain amortization termination benefits curtailments settlements net periodic benefit cost credit net periodic benefit cost credit pension postretirement benefit plans includes expenses curtailments settlements termination benefits provided certain employees connection spinoff organon connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments settlements recorded certain pension plans lump sum payments us pension plan participants also contributed settlements recorded components net periodic benefit cost credit service cost component included income expense net see note exception certain amounts termination benefits curtailments settlements recorded restructuring costs event giving rise termination benefits curtailment settlement related restructuring actions income discontinued operations net taxes amounts attributable noncontrolling interests related spinoff organon noted table contents obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities actuarial losses gains primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total us pension plans cash cash equivalents investment funds developed markets equities emerging markets equities real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments liabilities derivatives plan assets fair value international pension plans cash cash equivalents investment funds developed markets equities government agency obligations corporate obligations emerging markets equities fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance insurance contracts total contracts total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total cash cash equivalents investment funds developed markets equities emerging markets equities real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments liabilities derivatives plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations table contents although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions contributions expected approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income loss net gainloss amounts reflect differences expected actual returns plan assets well effects changes actuarial assumptions net gainloss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost arising period net loss gain amortization included benefit cost prior service credit cost amortization included benefit cost settlements curtailments table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate interest crediting rate benefit obligation discount rate salary growth rate interest crediting rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weightedaverage expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans compared health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate savings plans company also maintains defined contribution savings plans us company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses income loss investments equity securities net net periodic defined benefit plan credit cost service cost net includes net realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds unrealized gains losses investments directly owned determined end reporting period gains losses ownership interests investment funds accounted one quarter lag net reflected table includes million charge related settlements certain plaintiffs zetia antitrust litigation see note interest paid billion million million taxes income reconciliation effective tax rate income continuing operations us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income continuing operations taxes differential arising acquisition prometheus acquisition imago valuation allowances acquisitionrelated costs including amortization restructuring foreign earnings gilti foreignderived intangible income deduction rd tax credit state taxes inventory donations tax settlements acquisition pandion applicable impact changes uncertain tax positions reflected reconciling items companys remaining transition tax liability tax cuts jobs act tcja reduced payments expected utilization foreign tax credits billion december million included income taxes payable remainder million included noncurrent liabilities result transition tax tcja company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign withholding taxes would apply company remains indefinitely reinvested respect table contents financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates us particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire thereby yielding favorable impact effective tax rate compared us statutory rate company additional cantonal tax holiday switzerland provides tax rate reduction effective income continuing operations taxes consisted years ended december domestic foreign taxes income continuing operations consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities product intangibles licenses rd capitalization inventory related accelerated depreciation equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred tax assets nol carryforwards relate foreign jurisdictions valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards valuation allowances million established us tax credit carryforwards nol carryforwards income taxes paid including amounts attributable discontinued operations consisted years ended december domestic foreign includes tcja transition tax payments tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations spinoff organon balance december amount reflects settlement irs discussed table contents company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted expense benefit million million million amounts reflect beneficial impacts various tax settlements including settlement discussed liabilities accrued interest penalties million million december respectively internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment million million related continuing operations million related discontinued operations companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded million net tax benefit million related continuing operations million related discontinued operations net benefit reflects reductions reserves unrecognized tax benefits related liabilities tax positions relating years examination irs currently conducting examinations companys tax returns years including onetime transition tax enacted tcja irs disagrees companys transition tax position may result significant tax liability addition various state foreign tax examinations progress jurisdictions companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income continuing operations attributable merck co inc income discontinued operations net taxes amounts attributable noncontrolling interests net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders income continuing operations income discontinued operations net income earnings per common share assuming dilution attributable merck co inc common shareholders income continuing operations income discontinued operations net income issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss changes component comprehensive income loss follows employee foreign currency benefit translation accumulated derivatives plans adjustment comprehensive loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes spinoff organon see note balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes primarily relates foreign currency cash flow hedges reclassified aocl sales see note includes net amortization prior service cost actuarial gains losses settlements curtailments included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed product basis include two operating segments pharmaceutical animal health reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers farmers pet owners table contents sales companys products follows years ended december us intl total us intl total us intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima welireg alliance revenue reblozyl vaccines gardasilgardasil proquadmmr iivarivax rotateq vaxneuvance pneumovax vaqta hospital acute care bridion prevymis dificid zerbaxa noxafil primaxin cardiovascular alliance revenue adempasverquvo adempas virology lagevrio isentressisentress hd neuroscience belsomra immunology simponi remicade diabetes januvia janumet pharmaceutical total pharmaceutical segment sales animal health livestock companion animal total animal health segment sales total segment sales us plus international may equal total due rounding alliance revenue lynparza lenvima represents mercks share profits product sales net cost sales commercialization costs see note alliance revenue reblozyl represents royalties also includes payment received related achievement regulatory approval milestone see note alliance revenue adempasverquvo represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately primarily comprised miscellaneous corporate revenue including revenue hedging activities increased decreased sales million million million respectively well revenue thirdparty manufacturing arrangements including sales organon also includes million million million respectively related upfront milestone payments received merck outlicensing arrangements table contents consolidated sales geographic area derived follows years ended december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profits income continuing operations taxes follows years ended december segment profits pharmaceutical segment animal health segment total segment profits profits unallocated interest income interest expense amortization depreciation research development restructuring costs charge zetia antitrust litigation settlements unallocated net pharmaceutical segment profits comprised segment sales less standard costs well selling general administrative expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well selling general administrative expenses research development costs directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred merck research laboratories companys research development division focuses human healthrelated activities general administrative expenses directly incurred segments cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization intangible assets amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing arrangements unallocated net includes expenses corporate manufacturing cost centers intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value measurement liabilities contingent consideration miscellaneous income expense items table contents equity income affiliates depreciation included segment profits follows pharmaceutical animal health total year ended december included segment profits equity income affiliates depreciation year ended december included segment profits equity income affiliates depreciation year ended december included segment profits equity income affiliates depreciation property plant equipment net geographic area located follows december united states europe middle east africa asia pacific china japan latin america china japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors stockholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheet merck co inc subsidiaries company december related consolidated statements income comprehensive loss income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements companys internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate table contents critical audit matters critical audit matter communicated matter arising current period audit consolidated financial statements communicated required communicated audit committee relates accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matter providing separate opinion critical audit matter accounts disclosures relates us rebate accruals medicaid managed care medicare part described note consolidated financial statements company records certain variable consideration including discounts estimated time sale generally using expected value method amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued certain discounts representing portion accrual take form rebates amounts owed based upon definitive contractual agreements legal requirements private sector managed care public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers management uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision accrued balance relative provision rebates included accrued current liabilities billion december majority relates us rebate accruals medicaid managed care medicare part principal considerations determination performing procedures relating us rebate accruals medicaid managed care medicare part critical audit matter significant judgment management due significant measurement uncertainty involved developing rebate accruals accruals based assumptions developed using pricing information historical customer segment utilization mix high degree auditor judgment subjectivity effort performing procedures evaluating evidence related assumptions addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us rebate accruals medicaid managed care medicare part including managements controls assumptions used estimate corresponding rebate accruals procedures also included among others developing independent estimate rebate accruals utilizing third party data historical customer segment utilization mix us pricing information terms specific rebate programs historical trend actual rebate claims paid ii comparing independent estimate rebate accruals recorded management iii testing rebate claims paid including evaluating claims consistency contractual terms companys rebate agreements pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective fourth quarter changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule f act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule f securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls table contents may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein robert davis caroline litchfield chairman chief executive officer president executive vice president chief financial officer item b information insider trading arrangements three months ended december none companys directors executive officers adopted terminated rule b trading arrangements nonrule b trading arrangements item c disclosure regarding foreign jurisdictions prevent inspections applicable table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act applicable incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomcompany overviewcultureandvaluescodeofconductvaluesandstandards company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table ceo pay ratio pay vs performance table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related schedule director fees table director compensation table companys proxy statement annual meeting shareholders held may required information headings compensation management development committee interlocks insider participation compensation management development committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck co inc incentive stock plans merck co inc nonemployee directors stock option plan excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item